PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17716840-1	2008	The aim of the study was to develop a novel oral delivery system for the efflux pump substrate acyclovir (ACY) utilizing thiolated chitosan as excipient which is capable of inhibiting P-glycoprotein (P-gp).	Acyclovir	95-104	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	184-198
17716840-1	2008	The aim of the study was to develop a novel oral delivery system for the efflux pump substrate acyclovir (ACY) utilizing thiolated chitosan as excipient which is capable of inhibiting P-glycoprotein (P-gp).	Acyclovir	95-104	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	200-204
17716840-1	2008	The aim of the study was to develop a novel oral delivery system for the efflux pump substrate acyclovir (ACY) utilizing thiolated chitosan as excipient which is capable of inhibiting P-glycoprotein (P-gp).	Acyclovir	106-109	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	184-198
17716840-1	2008	The aim of the study was to develop a novel oral delivery system for the efflux pump substrate acyclovir (ACY) utilizing thiolated chitosan as excipient which is capable of inhibiting P-glycoprotein (P-gp).	Acyclovir	106-109	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	200-204
18974607-0	2008	Influence of ALDH2 genetic polymorphisms on aciclovir pharmacokinetics following oral administration of valaciclovir in Japanese end-stage renal disease patients.	Acyclovir	44-53	aldehyde dehydrogenase 2 family member	Homo sapiens	13-18
18683705-0	2008	[Experimental study of suppression of reactivation of herpes simplex virus type 1 by cyclooxygenase 2 inhibitor with acyclovir].	Acyclovir	117-126	prostaglandin-endoperoxide synthase 2	Homo sapiens	85-101
18342059-6	2008	In our three cases, aciclovir intravenous treatment (30mg/kg per day) enabled VZ virus clearing from the CSF and stopped the course of the vasculopathy.	Acyclovir	20-29	colony stimulating factor 2	Homo sapiens	105-108
17372819-1	2007	The effect of colitis induced with dextran sodium sulfate (DSS) in rats on the bioavailability of drugs transported by the oligopeptide transporter PepT-1 was analyzed by studying the pharmacokinetics of PepT-1 substrates: cephalexin and valacyclovir, the prodrug of antiviral acyclovir.	Acyclovir	241-250	solute carrier family 15 member 1	Rattus norvegicus	148-154
17881767-8	2007	Following treatment of the monolayers with poly (I:C), an innate immune activator that acts via TLR3, viral shedding was reduced significantly, comparable to levels seen when an antiviral formulation, acyclovir, was used.	Acyclovir	201-210	toll like receptor 3	Homo sapiens	96-100
17974026-1	2007	BACKGROUND: We evaluate the role of nerve growth factor (NGF) eye drops to treat a herpetic corneal ulcer resistant to systemic and local acyclovir treatment in an HIV-positive patient.	Acyclovir	138-147	nerve growth factor	Homo sapiens	36-55
17974026-1	2007	BACKGROUND: We evaluate the role of nerve growth factor (NGF) eye drops to treat a herpetic corneal ulcer resistant to systemic and local acyclovir treatment in an HIV-positive patient.	Acyclovir	138-147	nerve growth factor	Homo sapiens	57-60
17974026-6	2007	We recommend that trials of NGF therapy in herpetic keratitis should be carried out on a larger number of acyclovir resistant cases.	Acyclovir	106-115	nerve growth factor	Homo sapiens	28-31
15226381-3	2004	Enhanced bioavailability of VACV has been attributed to its carrier-mediated intestinal absorption via hPEPT1 peptide transporter followed by rapid and complete conversion to ACV.	Acyclovir	29-32	solute carrier family 15 member 1	Homo sapiens	103-109
16945492-8	2006	The release of aciclovir during the first days of the in vitro assay was improved with respect to microspheres without RAP.	Acyclovir	15-24	LDL receptor related protein associated protein 1	Homo sapiens	119-122
16982796-0	2006	Thymidine kinase mutations conferring acyclovir resistance in herpes simplex type 1 recombinant viruses.	Acyclovir	38-47	involved in nucleotide metabolism	Human alphaherpesvirus 1	0-16
16427262-5	2006	The inhibitory effect of SP-2a on virus adsorption occurred dose-dependently in all the HSV-1 strains tested, and the adsorption of the ACV-resistant DM2.1 strain was reduced by 81.9% (relative to control) with 4 microg/ml of the polysaccharide.	Acyclovir	136-139	surfactant protein A2	Homo sapiens	25-30
16427262-6	2006	This study clearly demonstrated that the antiviral mode of action of SP-2a is mediated mainly by inhibiting virus attachment to host cells, and this sulphated polysaccharide might have different modes of action against the ACV-sensitive and -resistant strains of HSV-1.	Acyclovir	223-226	surfactant protein A2	Homo sapiens	69-74
16381543-18	2005	Acyclovir 400 mg BID.	Acyclovir	0-9	BH3 interacting domain death agonist	Homo sapiens	17-20
15649395-2	2005	Recently, several structures of human PNP have been reported, which allowed redefinition of the active site and understanding of the structural basis for inhibition of PNP by acyclovir and immucillin-H.	Acyclovir	175-184	purine nucleoside phosphorylase	Homo sapiens	38-41
15649395-2	2005	Recently, several structures of human PNP have been reported, which allowed redefinition of the active site and understanding of the structural basis for inhibition of PNP by acyclovir and immucillin-H.	Acyclovir	175-184	purine nucleoside phosphorylase	Homo sapiens	168-171
15567284-0	2004	Acyclovir prodrug for the intestinal di/tri-peptide transporter PEPT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells.	Acyclovir	0-9	solute carrier family 15 member 1	Rattus norvegicus	64-69
15567284-1	2004	It has previously been shown that the prodrug Glu(acyclovir)-Sar has a high affinity for PEPT1 in Caco-2 cells.	Acyclovir	50-59	solute carrier family 15 member 1	Homo sapiens	89-94
17329857-1	2007	There is an interesting clinical report indicating that aciclovir, which is mainly excreted into urine, decreases the systemic clearance of theophylline by inhibiting cytochrome P450 (CYP) 1A2-mediated metabolism.	Acyclovir	56-65	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	167-192
17329857-5	2007	In place of theophylline, when 1-methyl-3-propylxanthine (2.5 mg/kg), which is almost metabolized by CYP1A2 in rats, was coadministered intravenously with aciclovir (50 mg/kg), the pharmacokinetics of 1-methyl-3-propylxanthine was also unchanged.	Acyclovir	155-164	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	101-107
16970995-0	2007	Resistance of herpes simplex virus type 1 to acyclovir: thymidine kinase gene mutagenesis study.	Acyclovir	45-54	involved in nucleotide metabolism	Human alphaherpesvirus 1	56-72
16970995-1	2007	By site-directed mutagenesis, we investigate the role of six mutations of herpes simplex virus type 1 thymidine kinase (TK) gene in the acquisition of resistance to acyclovir (ACV).	Acyclovir	165-174	involved in nucleotide metabolism	Human alphaherpesvirus 1	102-118
16970995-1	2007	By site-directed mutagenesis, we investigate the role of six mutations of herpes simplex virus type 1 thymidine kinase (TK) gene in the acquisition of resistance to acyclovir (ACV).	Acyclovir	165-174	involved in nucleotide metabolism	Human alphaherpesvirus 1	120-122
16970995-1	2007	By site-directed mutagenesis, we investigate the role of six mutations of herpes simplex virus type 1 thymidine kinase (TK) gene in the acquisition of resistance to acyclovir (ACV).	Acyclovir	176-179	involved in nucleotide metabolism	Human alphaherpesvirus 1	102-118
16970995-1	2007	By site-directed mutagenesis, we investigate the role of six mutations of herpes simplex virus type 1 thymidine kinase (TK) gene in the acquisition of resistance to acyclovir (ACV).	Acyclovir	176-179	involved in nucleotide metabolism	Human alphaherpesvirus 1	120-122
16876885-14	2006	Electromobility shift assays determined that resveratrol, in a dose dependent and reversible manner, suppressed activation of NF-kappaB in Vero cells infected with HSV-1, HSV-2 and acyclovir resistant HSV-1.	Acyclovir	181-190	nuclear factor kappa B subunit 1	Homo sapiens	126-135
16961277-2	2006	By using semiquantitative reverse transcription polymerase chain reaction (RT-PCR), the expressions of IL-2, IL-10 and TNF-alpha mRNA in control group, HSE group and acyclovir (ACV)-treated group were detected and the pathological changes of brain were observed.	Acyclovir	166-175	tumor necrosis factor	Mus musculus	119-128
16961277-2	2006	By using semiquantitative reverse transcription polymerase chain reaction (RT-PCR), the expressions of IL-2, IL-10 and TNF-alpha mRNA in control group, HSE group and acyclovir (ACV)-treated group were detected and the pathological changes of brain were observed.	Acyclovir	177-180	tumor necrosis factor	Mus musculus	119-128
16961277-4	2006	After treatment with ACV after HSV1 infection, the cerebral lesions in mice were improved, the level of IL-2 maintained stable, IL-10 was increased consistently, and TNF-alpha was decreased significantly as compared with those in HSE group.	Acyclovir	21-24	interleukin 2	Mus musculus	104-108
16961277-4	2006	After treatment with ACV after HSV1 infection, the cerebral lesions in mice were improved, the level of IL-2 maintained stable, IL-10 was increased consistently, and TNF-alpha was decreased significantly as compared with those in HSE group.	Acyclovir	21-24	interleukin 10	Mus musculus	128-133
16961277-4	2006	After treatment with ACV after HSV1 infection, the cerebral lesions in mice were improved, the level of IL-2 maintained stable, IL-10 was increased consistently, and TNF-alpha was decreased significantly as compared with those in HSE group.	Acyclovir	21-24	tumor necrosis factor	Mus musculus	166-175
15522398-0	2004	Ternary complexes metal [Co(II), Ni(II), Cu(II) and Zn(II)]--ortho-iodohippurate (I-hip)--acyclovir.	Acyclovir	90-99	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	25-31
15028478-9	2004	In vitro, Ad-hCG-beta-TK with acyclovir significantly inhibited NEC 8 growth but not PC-3 or WH cell growth.	Acyclovir	30-39	chorionic gonadotropin subunit beta 3	Homo sapiens	13-21
16028355-1	2004	Biphenyl hydrolase-like (BPHL) protein is a novel serine hydrolase which has been identified as human valacyclovirase (VACVase), catalyzing the hydrolytic activation of valine ester prodrugs of the antiviral drugs acyclovir and ganciclovir as well as other amino acid ester prodrugs of therapeutic nucleoside analogues.	Acyclovir	105-114	biphenyl hydrolase like	Homo sapiens	0-30
16028355-1	2004	Biphenyl hydrolase-like (BPHL) protein is a novel serine hydrolase which has been identified as human valacyclovirase (VACVase), catalyzing the hydrolytic activation of valine ester prodrugs of the antiviral drugs acyclovir and ganciclovir as well as other amino acid ester prodrugs of therapeutic nucleoside analogues.	Acyclovir	105-114	biphenyl hydrolase like	Homo sapiens	119-126
15325432-4	2004	All the results from this study suggested that the antiviral mode of action of SP2 could be ascribed to the inhibition of virus adsorption, which is different from that of the current drug of choice acyclovir.	Acyclovir	199-208	Sp2 transcription factor	Homo sapiens	79-82
15075326-10	2004	Acyclovir (100 microm to 5 mm), a pharmacological inhibitor of the ICln chloride channel, specifically inhibits integrin activation (PAC-1 expression) and platelet aggregation without affecting CD62 P expression confirming a specific role for ICln in integrin activation.	Acyclovir	0-9	chloride nucleotide-sensitive channel 1A pseudogene 1	Homo sapiens	67-71
15075326-10	2004	Acyclovir (100 microm to 5 mm), a pharmacological inhibitor of the ICln chloride channel, specifically inhibits integrin activation (PAC-1 expression) and platelet aggregation without affecting CD62 P expression confirming a specific role for ICln in integrin activation.	Acyclovir	0-9	dual specificity phosphatase 2	Homo sapiens	133-138
15075326-10	2004	Acyclovir (100 microm to 5 mm), a pharmacological inhibitor of the ICln chloride channel, specifically inhibits integrin activation (PAC-1 expression) and platelet aggregation without affecting CD62 P expression confirming a specific role for ICln in integrin activation.	Acyclovir	0-9	chloride nucleotide-sensitive channel 1A pseudogene 1	Homo sapiens	243-247
15205707-8	2004	CONCLUSION: Quercetin can enhance acyclovir intestinal absorption by inhibiting the function of P-gp.	Acyclovir	34-43	phosphoglycolate phosphatase	Homo sapiens	96-100
15832508-2	2004	The substrate specificity of BPHL was investigated with a series of amino acid ester prodrugs of the therapeutic nucleoside analogues: acyclovir, zidovudine, floxuridine, 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl) benzimidazole, and gemcitabine.	Acyclovir	135-144	biphenyl hydrolase like	Homo sapiens	29-33
15028478-10	2004	In vivo, Ad-hCG-beta-TK with acyclovir significantly inhibited NEC 8 subcutaneous tumor growth in nude mice.	Acyclovir	29-38	chorionic gonadotropin subunit beta 3	Homo sapiens	12-20
15832499-1	2004	The objective of this work was to design an acyclovir prodrug that would utilize the human apical sodium-dependent bile acid transporter (hASBT) and enhance acyclovir oral bioavailability.	Acyclovir	44-53	solute carrier family 10 member 2	Homo sapiens	138-143
15832499-1	2004	The objective of this work was to design an acyclovir prodrug that would utilize the human apical sodium-dependent bile acid transporter (hASBT) and enhance acyclovir oral bioavailability.	Acyclovir	157-166	solute carrier family 10 member 2	Homo sapiens	138-143
15832499-8	2004	Relative to cellular uptake studies of acyclovir alone, the cellular uptake from the prodrug resulted in a 16-fold greater acyclovir accumulation within hASBT-COS cells, indicating enhanced permeation properties of the prodrug.	Acyclovir	123-132	solute carrier family 10 member 2	Homo sapiens	153-158
15832499-10	2004	The extent of acyclovir uptake in the presence of sodium was 1.4-fold greater than the extent of passive prodrug uptake in the absence of sodium (p = 0.02), indicating translocation of the prodrug by hASBT.	Acyclovir	14-23	solute carrier family 10 member 2	Homo sapiens	200-205
12732646-3	2003	The increased bioavailability of valacyclovir is attributed to carrier-mediated intestinal absorption, via the hPEPT1 peptide transporter, followed by the rapid and complete conversion to acyclovir.	Acyclovir	36-45	solute carrier family 15 member 1	Homo sapiens	111-117
14675048-0	2004	Down-regulation of Na+ transporters and AQP2 is responsible for acyclovir-induced polyuria and hypophosphatemia.	Acyclovir	64-73	aquaporin 2	Rattus norvegicus	40-44
14708229-3	2003	The stimulated activity of Th1, B-lymphocytes and of natural killers (NK) as well as suppression of Th2 occurred in the initial treatment stage by acyclovir (10 days), which brought about a positive clinical effect in a majority of cases.	Acyclovir	147-156	negative elongation factor complex member C/D	Homo sapiens	27-30
12750437-9	2003	The highly negative correlations observed with known efflux pumps such as MDR1 (P-glycoprotein) and MRP2 (cMOAT), as well as with the CYP450 IIIA subfamily may indicate that these proteins may regulate the cellular accumulation and metabolism of acyclovir.	Acyclovir	246-255	ATP binding cassette subfamily B member 1	Homo sapiens	74-78
12750437-9	2003	The highly negative correlations observed with known efflux pumps such as MDR1 (P-glycoprotein) and MRP2 (cMOAT), as well as with the CYP450 IIIA subfamily may indicate that these proteins may regulate the cellular accumulation and metabolism of acyclovir.	Acyclovir	246-255	ATP binding cassette subfamily B member 1	Homo sapiens	80-94
12750437-9	2003	The highly negative correlations observed with known efflux pumps such as MDR1 (P-glycoprotein) and MRP2 (cMOAT), as well as with the CYP450 IIIA subfamily may indicate that these proteins may regulate the cellular accumulation and metabolism of acyclovir.	Acyclovir	246-255	ATP binding cassette subfamily C member 2	Homo sapiens	100-104
12750437-9	2003	The highly negative correlations observed with known efflux pumps such as MDR1 (P-glycoprotein) and MRP2 (cMOAT), as well as with the CYP450 IIIA subfamily may indicate that these proteins may regulate the cellular accumulation and metabolism of acyclovir.	Acyclovir	246-255	ATP binding cassette subfamily C member 2	Homo sapiens	106-111
12821497-3	2003	Coadministration of the human peptide transporter 1 (hPEPT1) substrates valacyclovir and cephalexin minimally reduced the acyclovir AUC.	Acyclovir	75-84	cadherin 17	Homo sapiens	24-51
12821497-3	2003	Coadministration of the human peptide transporter 1 (hPEPT1) substrates valacyclovir and cephalexin minimally reduced the acyclovir AUC.	Acyclovir	75-84	solute carrier family 15 member 1	Homo sapiens	53-59
12816347-5	2003	Drug molecules such as oral active beta-lactam antibiotics, bestatin, prodrugs of aciclovir and ganciclovir have oral bioavailabilities, which largely are a result of their interaction with PepT1.	Acyclovir	82-91	solute carrier family 15 member 1	Homo sapiens	190-195
12767468-0	2003	Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir.	Acyclovir	110-119	lactotransferrin	Homo sapiens	16-29
12526824-1	2003	A general drug delivery approach for increasing oral bioavailability of purine and pyrimidine analogues such as acyclovir may be to link these compounds reversibly to stabilized dipeptide pro-moieties with affinity for the human intestinal di/tri-peptide transporter, hPepT1.	Acyclovir	112-121	solute carrier family 15 member 1	Homo sapiens	268-274
12526824-2	2003	In the present study, novel L-Glu-Sar and D-Glu-Ala ester prodrugs of acyclovir and 1-(2-hydroxyethyl)-linked thymine were synthesized and their affinities for hPepT1 in Caco-2 cells were determined.	Acyclovir	70-79	solute carrier family 15 member 1	Homo sapiens	160-166
12760570-1	2003	The aim of the present work was to investigate the possibility of achieving buccal delivery of a problematic drug, acyclovir, from films based on chitosan hydrochloride (HCS) and polyacrylic acid sodium salt (PAA).	Acyclovir	115-124	holocarboxylase synthetase	Homo sapiens	170-173
12406508-0	2002	Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain.	Acyclovir	105-114	involved in nucleotide metabolism	Human alphaherpesvirus 1	49-65
12760570-12	2003	The film based on 1/1.3 HCS/PAA weight ratio, besides possessing the best resilience properties on the mucosa, was also characterized by the highest permeation profile and, therefore, represents a promising formulation for buccal delivery of acyclovir.	Acyclovir	242-251	holocarboxylase synthetase	Homo sapiens	24-27
12388715-7	2002	For two of the three virus strains tested, IFN-beta and IFN-gamma inhibit HSV-1 replication with a potency that approaches that achieved by a high dose of acyclovir.	Acyclovir	155-164	interferon beta 1, fibroblast	Mus musculus	43-51
12388715-7	2002	For two of the three virus strains tested, IFN-beta and IFN-gamma inhibit HSV-1 replication with a potency that approaches that achieved by a high dose of acyclovir.	Acyclovir	155-164	interferon gamma	Mus musculus	56-65
12086147-3	2002	The UL7 protein was produced in the late phase of infection, and its synthesis was highly inhibited, but not abolished by the addition of acyclovir (ACV).	Acyclovir	138-147	involved in virion morphogenesis	Human alphaherpesvirus 2	4-7
12113886-1	2002	L-Valacyclovir, a prodrug of acyclovir, is a substrate for the peptide transporter (PepT1) in the intestinal mucosa, which accounts for its higher than expected oral bioavailability.	Acyclovir	5-14	solute carrier family 15 member 1	Homo sapiens	84-89
12358729-6	2002	Xenopus oocytes expressing OAT3 were found to exhibit [(3)H]indoxyl sulfate uptake, which was significantly inhibited by neurotransmitter metabolites, such as homovanillic acid and 3-methoxy-4-hydroxymandelic acid, and by acyclovir, cefazolin, baclofen, 6-mercaptopurine, benzoic acid, and ketoprofen.	Acyclovir	222-231	solute carrier family 22 member 8	Rattus norvegicus	27-31
12086147-3	2002	The UL7 protein was produced in the late phase of infection, and its synthesis was highly inhibited, but not abolished by the addition of acyclovir (ACV).	Acyclovir	149-152	involved in virion morphogenesis	Human alphaherpesvirus 2	4-7
11861798-8	2002	In addition, probenecid weakly inhibited the hOAT1-mediated ACV uptake.	Acyclovir	60-63	solute carrier family 22 member 6	Homo sapiens	45-50
11861798-3	2002	Time- and concentration-dependent uptake of ACV and GCV was observed in hOAT1- and hOCT1-expressing cells.	Acyclovir	44-47	solute carrier family 22 member 6	Homo sapiens	72-77
11861798-9	2002	In conclusion, these results suggest that hOAT1 and hOCT1 mediate renal ACV and GCV transport, whereas hOAT1, hOAT2, hOAT3, and hOAT4 mediate renal AZT transport.	Acyclovir	72-75	solute carrier family 22 member 6	Homo sapiens	42-47
11861798-9	2002	In conclusion, these results suggest that hOAT1 and hOCT1 mediate renal ACV and GCV transport, whereas hOAT1, hOAT2, hOAT3, and hOAT4 mediate renal AZT transport.	Acyclovir	72-75	solute carrier family 22 member 1	Homo sapiens	52-57
11861798-3	2002	Time- and concentration-dependent uptake of ACV and GCV was observed in hOAT1- and hOCT1-expressing cells.	Acyclovir	44-47	solute carrier family 22 member 1	Homo sapiens	83-88
11694014-0	2001	Comparative permeability of some acyclovir derivatives through native mucus and crude mucin dispersions.	Acyclovir	33-42	LOC100508689	Homo sapiens	86-91
11861798-4	2002	In contrast, uptake of valacyclovir, L-valyl ester of ACV, was observed only in hOAT3-expressing cells.	Acyclovir	54-57	solute carrier family 22 member 8	Homo sapiens	80-85
11861798-6	2002	The Km values of ACV uptake by hOAT1 and hOCT1 were 342.3 and 151.2 microM, respectively, whereas those of GCV uptake by hOAT1 and hOCT1 were 895.5 and 516.2 microM, respectively.	Acyclovir	17-20	solute carrier family 22 member 6	Homo sapiens	31-36
11861798-6	2002	The Km values of ACV uptake by hOAT1 and hOCT1 were 342.3 and 151.2 microM, respectively, whereas those of GCV uptake by hOAT1 and hOCT1 were 895.5 and 516.2 microM, respectively.	Acyclovir	17-20	solute carrier family 22 member 1	Homo sapiens	41-46
11786216-6	2002	The expression of iNOS mRNA was suppressed by L-NA and by acyclovir/corticosteroids.	Acyclovir	58-67	nitric oxide synthase 2, inducible	Mus musculus	18-22
11602757-5	2001	When TG cultures were treated with acyclovir for 4 days to insure uniform latency, supplementation with recombinant IFN-gamma blocked HSV-1 reactivation in 80% of cultures when endogenous CD8(+) T cells were present and significantly reduced and delayed HSV-1 reactivation when CD8(+) T cells or CD45(+) cells were depleted from the TG cultures.	Acyclovir	35-44	interferon gamma	Homo sapiens	116-125
11602757-6	2001	The effectiveness of recombinant IFN-gamma in blocking HSV-1 reactivation was lost when its addition to TG cultures was delayed by more than 24 h after acyclovir removal.	Acyclovir	152-161	interferon gamma	Homo sapiens	33-42
11505446-0	2001	Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein.	Acyclovir	0-9	tegument serine/threonine protein kinase	Human betaherpesvirus 5	142-146
11160743-11	2001	Finally, treatment with phosphonoacetic acid or acyclovir prior to induction with PMA, anti-Ig, or TGF-beta blocked the protective effect in Mutu-I cells.	Acyclovir	48-57	transforming growth factor beta 1	Homo sapiens	99-107
11356082-3	2001	Activation of GCV and ACV, after an initial phosphorylation step by the viral thymidine kinase, is carried out by guanylate kinase.	Acyclovir	22-25	guanylate kinase 1	Sus scrofa	114-130
11356082-4	2001	We reasoned that coexpression of guanylate kinase (GK) with HSV-TK would augment phosphorylation of GCV or ACV, leading to increased cell killing.	Acyclovir	107-110	guanylate kinase 1	Sus scrofa	33-49
11356082-4	2001	We reasoned that coexpression of guanylate kinase (GK) with HSV-TK would augment phosphorylation of GCV or ACV, leading to increased cell killing.	Acyclovir	107-110	guanylate kinase 1	Sus scrofa	51-53
11440418-0	2001	Coma secondary to aciclovir neurotoxicity.	Acyclovir	18-27	COMA	Homo sapiens	0-4
11076113-5	2000	The percentage acyclovir extraction was 84% and 60% during CVVHD and CVVHDF with F-8 and CA-210 dialyzers, respectively.	Acyclovir	15-24	coagulation factor VIII	Homo sapiens	81-84
11076113-6	2000	Acyclovir clearance during CVVHD was 14 ml/min and during CVVHDF was 17 ml/min, with F-8 and CA-210 dialyzers, respectively.	Acyclovir	0-9	coagulation factor VIII	Homo sapiens	85-88
11180195-1	2000	Carrier-mediated transport of valacyclovir (vacv), the L-valyl ester prodrug of acyclovir (acv), via the human peptide transporter (hPepT1) has been shown in Xenopus laevis oocytes and in cell lines such as Chinese hamster ovary (CHO) and Caco-2 transfected with the hPepT1 gene.	Acyclovir	33-42	solute carrier family 15 member 1	Homo sapiens	132-138
10945832-0	2000	Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.	Acyclovir	77-86	solute carrier family 22 member 6	Rattus norvegicus	18-45
10945832-0	2000	Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.	Acyclovir	77-86	solute carrier family 22 member 6	Rattus norvegicus	47-52
10945832-4	2000	Oocytes injected with rOAT1 cRNA showed significantly higher uptake of zidovudine (AZT) and acyclovir (ACV) than control oocytes.	Acyclovir	92-101	solute carrier family 22 member 6	Rattus norvegicus	22-27
10945832-4	2000	Oocytes injected with rOAT1 cRNA showed significantly higher uptake of zidovudine (AZT) and acyclovir (ACV) than control oocytes.	Acyclovir	103-106	solute carrier family 22 member 6	Rattus norvegicus	22-27
10945832-5	2000	rOAT1-mediated uptake of AZT and ACV was probenecid-sensitive and increased by the outwardly directed gradient of glutarate.	Acyclovir	33-36	solute carrier family 22 member 6	Rattus norvegicus	0-5
10945832-6	2000	The affinity of rOAT1 for AZT and ACV was determined to be 68 and 242 microM, respectively.	Acyclovir	34-37	solute carrier family 22 member 6	Rattus norvegicus	16-21
11180195-1	2000	Carrier-mediated transport of valacyclovir (vacv), the L-valyl ester prodrug of acyclovir (acv), via the human peptide transporter (hPepT1) has been shown in Xenopus laevis oocytes and in cell lines such as Chinese hamster ovary (CHO) and Caco-2 transfected with the hPepT1 gene.	Acyclovir	33-42	solute carrier family 15 member 1	Homo sapiens	267-273
11180195-1	2000	Carrier-mediated transport of valacyclovir (vacv), the L-valyl ester prodrug of acyclovir (acv), via the human peptide transporter (hPepT1) has been shown in Xenopus laevis oocytes and in cell lines such as Chinese hamster ovary (CHO) and Caco-2 transfected with the hPepT1 gene.	Acyclovir	45-48	solute carrier family 15 member 1	Homo sapiens	132-138
11180195-1	2000	Carrier-mediated transport of valacyclovir (vacv), the L-valyl ester prodrug of acyclovir (acv), via the human peptide transporter (hPepT1) has been shown in Xenopus laevis oocytes and in cell lines such as Chinese hamster ovary (CHO) and Caco-2 transfected with the hPepT1 gene.	Acyclovir	45-48	solute carrier family 15 member 1	Homo sapiens	267-273
10320031-1	1999	The effect of acyclovir treatment on viral burden and the expression of immunologic nitric oxide synthase (iNOS) within brains of 42 HSV-1 F infected mice was studied by using a titration PCR assay for HSV-1 DNA and a semiquantitative RT-PCR for iNOS mRNA.	Acyclovir	14-23	nitric oxide synthase 2	Homo sapiens	107-111
10699766-5	2000	PCR analyses demonstrated that the R1, R5 and the Pst I-sites were stable and useful in epidemiological studies even after ACV treatment.	Acyclovir	123-126	CD1b molecule	Homo sapiens	35-41
10708440-10	2000	Treatment with inhibitors of viral DNA polymerase, such as phosphonoacetic acid and acyclovir, reduced but did not abolish the transcription of BFRF1, thus indicating that BFRF1 can be classified as an early gene.	Acyclovir	84-93	nuclear egress membrane protein	Human gammaherpesvirus 4	172-177
10563086-0	1999	[Acyclovir may modulate clonal expansion of cd8+ lymphocytes induced by the Cytomegalovirus antigen].	Acyclovir	1-10	CD8a molecule	Homo sapiens	44-47
10563086-7	1999	On addition of acyclovir to the cell culture a moderate reduction was produced in lymphoproliferative response versus the CMV antigen and HVS, characteristically modulating CD8+ cell proliferation, thereby leading to reestablishment of the CD4/CD8 quotient.	Acyclovir	15-24	CD8a molecule	Homo sapiens	173-176
10428917-0	1999	Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein.	Acyclovir	0-9	tegument serine/threonine protein kinase	Human betaherpesvirus 5	57-61
10418043-6	1999	Median CD4 lymphocytes was 18/mm3 (0-232) among the 12 patients with ACV prophylaxis.	Acyclovir	69-72	CD4 molecule	Homo sapiens	7-10
10360320-4	1999	Inhibition of VZV replication in HCS cells by acyclovir (ACV), recombinant human interferon-alpha 2a (IFN-alpha 2a), or the combination of these two antivirals was detected by both an infectious centers-plaque-reduction assay and an ELISA method using monoclonal anti-VZV antibody.	Acyclovir	57-60	holocarboxylase synthetase	Homo sapiens	33-36
10230661-3	1999	Anti-viral therapy with acyclovir should be started whenever HSE is suspected.	Acyclovir	24-33	hydroxysteroid 17-beta dehydrogenase 6	Homo sapiens	61-64
10882609-0	2000	Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients.	Acyclovir	50-59	involved in nucleotide metabolism	Human alphaherpesvirus 1	28-44
10790110-1	2000	A rapid phenotypic screening method for herpes simplex virus (HSV) and varicella-zoster virus (VZV) thymidine kinase (TK) genes was developed for monitoring acyclovir-resistant viruses.	Acyclovir	157-166	thymidine kinase	Human alphaherpesvirus 3	100-116
10790110-1	2000	A rapid phenotypic screening method for herpes simplex virus (HSV) and varicella-zoster virus (VZV) thymidine kinase (TK) genes was developed for monitoring acyclovir-resistant viruses.	Acyclovir	157-166	thymidine kinase	Human alphaherpesvirus 3	118-120
10841074-7	2000	Analogous to treatment of virus-infected cells, suboptimal concentrations of ACV were as effective as high concentrations when used in conjunction with low concentrations of IFN-gamma in inhibition of tumor cell growth.	Acyclovir	77-80	interferon gamma	Homo sapiens	174-183
10841074-9	2000	The cooperative effect of ACV and IFN-gamma against the glioblastomas appears to be due to direct inhibition of DNA synthesis by ACV in the S phase of the cell cycle and induction by IFN-gamma of the tumor suppressor gene p21wAF1/CIP1, which in turn acts at the level of proliferating cell nuclear antigen (PCNA) and cyclin E/cyclin-dependent kinase 2 (Cdk2) binding and inhibition of function.	Acyclovir	26-29	interferon gamma	Homo sapiens	183-192
10841074-9	2000	The cooperative effect of ACV and IFN-gamma against the glioblastomas appears to be due to direct inhibition of DNA synthesis by ACV in the S phase of the cell cycle and induction by IFN-gamma of the tumor suppressor gene p21wAF1/CIP1, which in turn acts at the level of proliferating cell nuclear antigen (PCNA) and cyclin E/cyclin-dependent kinase 2 (Cdk2) binding and inhibition of function.	Acyclovir	26-29	cyclin dependent kinase inhibitor 1A	Homo sapiens	222-234
10841074-9	2000	The cooperative effect of ACV and IFN-gamma against the glioblastomas appears to be due to direct inhibition of DNA synthesis by ACV in the S phase of the cell cycle and induction by IFN-gamma of the tumor suppressor gene p21wAF1/CIP1, which in turn acts at the level of proliferating cell nuclear antigen (PCNA) and cyclin E/cyclin-dependent kinase 2 (Cdk2) binding and inhibition of function.	Acyclovir	26-29	proliferating cell nuclear antigen	Homo sapiens	271-312
10841074-9	2000	The cooperative effect of ACV and IFN-gamma against the glioblastomas appears to be due to direct inhibition of DNA synthesis by ACV in the S phase of the cell cycle and induction by IFN-gamma of the tumor suppressor gene p21wAF1/CIP1, which in turn acts at the level of proliferating cell nuclear antigen (PCNA) and cyclin E/cyclin-dependent kinase 2 (Cdk2) binding and inhibition of function.	Acyclovir	26-29	cyclin dependent kinase 2	Homo sapiens	353-357
10841074-9	2000	The cooperative effect of ACV and IFN-gamma against the glioblastomas appears to be due to direct inhibition of DNA synthesis by ACV in the S phase of the cell cycle and induction by IFN-gamma of the tumor suppressor gene p21wAF1/CIP1, which in turn acts at the level of proliferating cell nuclear antigen (PCNA) and cyclin E/cyclin-dependent kinase 2 (Cdk2) binding and inhibition of function.	Acyclovir	129-132	interferon gamma	Homo sapiens	34-43
10759680-11	2000	The mean PCNA labelling index in prostate cancer cells of mice treated with Ad-CMV-TK/acyclovir was significantly lower than that in untreated controls (P < 0.05, Mann-Whitney U-test).	Acyclovir	86-95	proliferating cell nuclear antigen	Mus musculus	9-13
10649983-2	2000	Among the compounds synthesized, (E)-5-halovinyluracil derivatives showed superior anti-varicella zoster virus (VZV) activity over acyclovir (ACV) but were less potent than ACV against herpes symplex virus type-1 (HSV-1).	Acyclovir	131-140	Rho guanine nucleotide exchange factor 15	Rattus norvegicus	33-38
10649983-2	2000	Among the compounds synthesized, (E)-5-halovinyluracil derivatives showed superior anti-varicella zoster virus (VZV) activity over acyclovir (ACV) but were less potent than ACV against herpes symplex virus type-1 (HSV-1).	Acyclovir	142-145	Rho guanine nucleotide exchange factor 15	Rattus norvegicus	33-38
10525090-4	1999	Valacyclovir, the L-valyl ester prodrug of the antiherpetic agent acyclovir, competitively inhibited [(14)C]glycylsarcosine uptake in the rPEPT1- or rPEPT2-expressing cells.	Acyclovir	3-12	solute carrier family 15 member 1	Rattus norvegicus	138-144
10508017-0	1999	Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir.	Acyclovir	121-130	thymidine kinase	Human alphaherpesvirus 3	43-59
10563086-7	1999	On addition of acyclovir to the cell culture a moderate reduction was produced in lymphoproliferative response versus the CMV antigen and HVS, characteristically modulating CD8+ cell proliferation, thereby leading to reestablishment of the CD4/CD8 quotient.	Acyclovir	15-24	CD4 molecule	Homo sapiens	240-243
10563086-7	1999	On addition of acyclovir to the cell culture a moderate reduction was produced in lymphoproliferative response versus the CMV antigen and HVS, characteristically modulating CD8+ cell proliferation, thereby leading to reestablishment of the CD4/CD8 quotient.	Acyclovir	15-24	CD8a molecule	Homo sapiens	244-247
10428917-4	1999	Anabolism studies with the HCMV wild-type strain AD169 and with recombinant mutants derived from marker transfer experiments performed by using mutant UL97 DNA from both clinical isolates and a laboratory-derived strain resistant to GCV showed that mutations in the UL97 gene cripple the ability of recombinant virus-infected cells to anabolize both GCV and ACV.	Acyclovir	358-361	tegument serine/threonine protein kinase	Human betaherpesvirus 5	266-270
10428917-5	1999	These mutant UL97 recombinant viruses were less susceptible to both GCV and ACV than was the wild-type strain.	Acyclovir	76-79	tegument serine/threonine protein kinase	Human betaherpesvirus 5	13-17
10428917-6	1999	A recombinant herpes simplex virus type 1 strain, in which the thymidine kinase gene is deleted and the UL13 gene is replaced with the HCMV UL97 gene, was able to induce the phosphorylation of ACV in infected cells.	Acyclovir	193-196	tegument serine/threonine protein kinase	Human alphaherpesvirus 1	104-108
10428917-6	1999	A recombinant herpes simplex virus type 1 strain, in which the thymidine kinase gene is deleted and the UL13 gene is replaced with the HCMV UL97 gene, was able to induce the phosphorylation of ACV in infected cells.	Acyclovir	193-196	tegument serine/threonine protein kinase	Human betaherpesvirus 5	140-144
10428917-7	1999	Finally, purified UL97 phosphorylated both GCV and ACV to their monophosphates.	Acyclovir	51-54	tegument serine/threonine protein kinase	Human betaherpesvirus 5	18-22
10428917-8	1999	Our results indicate that UL97 promotes the selective activity of ACV against HCMV.	Acyclovir	66-69	tegument serine/threonine protein kinase	Human betaherpesvirus 5	26-30
10421406-0	1999	Nucleotide sequence of thymidine kinase gene of sequential acyclovir-resistant herpes simplex virus type 1 isolates recovered from a child with Wiskott-Aldrich syndrome: evidence for reactivation of acyclovir-resistant herpes simplex virus.	Acyclovir	59-68	involved in nucleotide metabolism	Human alphaherpesvirus 1	23-39
10421406-0	1999	Nucleotide sequence of thymidine kinase gene of sequential acyclovir-resistant herpes simplex virus type 1 isolates recovered from a child with Wiskott-Aldrich syndrome: evidence for reactivation of acyclovir-resistant herpes simplex virus.	Acyclovir	199-208	involved in nucleotide metabolism	Human alphaherpesvirus 1	23-39
10360320-4	1999	Inhibition of VZV replication in HCS cells by acyclovir (ACV), recombinant human interferon-alpha 2a (IFN-alpha 2a), or the combination of these two antivirals was detected by both an infectious centers-plaque-reduction assay and an ELISA method using monoclonal anti-VZV antibody.	Acyclovir	46-55	holocarboxylase synthetase	Homo sapiens	33-36
10189905-12	1999	Intravenous aciclovir should be reserved for severe disseminated and/or neurological forms and for highly immunodepressed patients (for example those with a CD4 count below 200/mm3).	Acyclovir	12-21	CD4 molecule	Homo sapiens	157-160
10320031-1	1999	The effect of acyclovir treatment on viral burden and the expression of immunologic nitric oxide synthase (iNOS) within brains of 42 HSV-1 F infected mice was studied by using a titration PCR assay for HSV-1 DNA and a semiquantitative RT-PCR for iNOS mRNA.	Acyclovir	14-23	nitric oxide synthase 2	Homo sapiens	246-250
10320031-3	1999	Following infection, a parallel increase of iNOS mRNA and HSV-1F-DNA occurred with peaks after 7 days that were both significantly lower under acyclovir treatment.	Acyclovir	143-152	nitric oxide synthase 2	Homo sapiens	44-48
10320031-5	1999	This suggests that acyclovir decreases iNOS expression via inhibition of viral replication shortly after infection but fails to influence elevated iNOS within the brain late in the course of experimental HSVE.	Acyclovir	19-28	nitric oxide synthase 2	Homo sapiens	39-43
9731864-6	1998	RESULTS: Compared with placebo, prophylactic acyclovir completely inhibited acute viral replication as evidenced by the absence of beta-galactosidase activity (P < .001) and significantly decreased the number of neurons harboring latent infection (P = .01).	Acyclovir	45-54	galactosidase, beta 1	Mus musculus	131-149
10100299-0	1999	"5"-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter,".	Acyclovir	48-57	solute carrier family 15 member 1	Homo sapiens	98-103
9778999-7	1998	Four of the 12 augmented the therapeutic efficacy of acyclovir (ACV) in mice and showed potent anti-HSV activity against infection with ACV-resistant HSV-1 mutants in mice.	Acyclovir	136-139	NDV-induced circulating interferon, X-linked	Mus musculus	150-155
9753615-3	1998	Vacv uptake was found to be concentration dependent, saturable (K(m) = 5.94 +/- 1.91 mM and Jmax = 1.68 +/- 0.25 nmoles/hr/oocyte), pH dependent, and inhibited by various known substrates of hPepT1 but not by acv, valine or pentaglycine.	Acyclovir	1-4	solute carrier family 15 member 1	Homo sapiens	191-197
9755889-2	1998	METHODS: Amino acid ester prodrugs of acyclovir and AZT were synthesized and their apical membrane permeability and hydrolysis were evaluated in Caco-2/hPEPT1 cells.	Acyclovir	38-47	solute carrier family 15 member 1	Homo sapiens	152-158
9706043-0	1998	5"-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.	Acyclovir	47-56	solute carrier family 15 member 1	Homo sapiens	97-102
9375008-5	1997	However, there was a significant reduction in the titer of antibody specific for glycoprotein D and glycoprotein B but not glycoprotein H/L 120 days PI in the acyclovir-treated compared to vehicle-treated mice.	Acyclovir	159-168	atypical chemokine receptor 1 (Duffy blood group)	Mus musculus	81-114
9707372-7	1998	These studies suggest that the synergistic anti-HSV activities of IFN-alpha with ACV could be mediated, in part, through some post-transcriptional mechanism induced by IFN-alpha treatment, leading to the reduction in production of viral early enzymes, especially DNA polymerase.	Acyclovir	81-84	interferon alpha 1	Homo sapiens	66-75
9707372-7	1998	These studies suggest that the synergistic anti-HSV activities of IFN-alpha with ACV could be mediated, in part, through some post-transcriptional mechanism induced by IFN-alpha treatment, leading to the reduction in production of viral early enzymes, especially DNA polymerase.	Acyclovir	81-84	interferon alpha 1	Homo sapiens	168-177
9455514-0	1998	Acyclovir use and survival among human immunodeficiency virus-infected patients with CD4 cell counts of < 500/mm3.	Acyclovir	0-9	CD4 molecule	Homo sapiens	85-88
9455514-6	1998	Individuals reporting acyclovir use were more likely to be white, male, and homosexual; to have a history of herpes simplex and zoster; and to have lower CD4+ T cell counts than those who did not.	Acyclovir	22-31	CD4 molecule	Homo sapiens	154-157
10189189-8	1998	The induction of IL-10(h+v) and vIL-10 was inhibited with a tyrosine kinase inhibitor, herbimycin, or with an inhibitor of herpesvirus DNA polymerase, phosphonoacetic acid, or acyclovir.	Acyclovir	176-185	interleukin 10	Homo sapiens	17-22
9695629-12	1998	However, when the differentiation should be difficult, we believe that the administration of ACV can be carefully continued because the potential fatality of HSE is high while ACV neurotoxicity is reversible.	Acyclovir	93-96	hydroxysteroid 17-beta dehydrogenase 6	Homo sapiens	158-161
9707372-1	1998	Treatment of cells with combinations of human interferon-alpha (IFN-alpha) and the nucleoside analog, acyclovir (ACV), leads to the synergistic inhibition of herpes simplex virus type 1 (HSV-1) replication.	Acyclovir	113-116	interferon alpha 1	Homo sapiens	64-73
9707372-3	1998	Combination treatment with 100 IU/ml IFN-alpha and 5 microM ACV led to HSV-1 DNA levels more than 8-fold lower than in cells treated with ACV alone, while IFN-alpha treatment alone had no detectable effect on viral DNA synthesis.	Acyclovir	138-141	interferon alpha 1	Homo sapiens	37-46
9514106-7	1998	The nucleoside analogue aciclovir (syn: acyclovir, Zovirax) is effective in inhibiting replication of VZV when given at a dosage higher than that required for treatment of HSV, and is currently the only available and approved treatment for varicella in the U.K. Intravenous aciclovir therapy for 5-10 days is effective for varicella in neonates and the immunocompromised, and for varicella pneumonia or other complications in adults and children, if begun early.	Acyclovir	24-33	synemin	Homo sapiens	35-38
9514106-7	1998	The nucleoside analogue aciclovir (syn: acyclovir, Zovirax) is effective in inhibiting replication of VZV when given at a dosage higher than that required for treatment of HSV, and is currently the only available and approved treatment for varicella in the U.K. Intravenous aciclovir therapy for 5-10 days is effective for varicella in neonates and the immunocompromised, and for varicella pneumonia or other complications in adults and children, if begun early.	Acyclovir	40-49	synemin	Homo sapiens	35-38
9514106-7	1998	The nucleoside analogue aciclovir (syn: acyclovir, Zovirax) is effective in inhibiting replication of VZV when given at a dosage higher than that required for treatment of HSV, and is currently the only available and approved treatment for varicella in the U.K. Intravenous aciclovir therapy for 5-10 days is effective for varicella in neonates and the immunocompromised, and for varicella pneumonia or other complications in adults and children, if begun early.	Acyclovir	51-58	synemin	Homo sapiens	35-38
9514106-7	1998	The nucleoside analogue aciclovir (syn: acyclovir, Zovirax) is effective in inhibiting replication of VZV when given at a dosage higher than that required for treatment of HSV, and is currently the only available and approved treatment for varicella in the U.K. Intravenous aciclovir therapy for 5-10 days is effective for varicella in neonates and the immunocompromised, and for varicella pneumonia or other complications in adults and children, if begun early.	Acyclovir	274-283	synemin	Homo sapiens	35-38
9375008-8	1997	However, 120 days p.i., IFN-gamma and TNF-alpha mRNA were approaching baseline levels in TG of acyclovir-treated mice, but remained significantly elevated in untreated controls (i.e., IFN-gamma mRNA levels were sixfold higher in TG of untreated mice).	Acyclovir	95-104	interferon gamma	Mus musculus	24-33
9375008-8	1997	However, 120 days p.i., IFN-gamma and TNF-alpha mRNA were approaching baseline levels in TG of acyclovir-treated mice, but remained significantly elevated in untreated controls (i.e., IFN-gamma mRNA levels were sixfold higher in TG of untreated mice).	Acyclovir	95-104	tumor necrosis factor	Mus musculus	38-47
9375008-8	1997	However, 120 days p.i., IFN-gamma and TNF-alpha mRNA were approaching baseline levels in TG of acyclovir-treated mice, but remained significantly elevated in untreated controls (i.e., IFN-gamma mRNA levels were sixfold higher in TG of untreated mice).	Acyclovir	95-104	interferon gamma	Mus musculus	184-193
9330759-0	1997	Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses.	Acyclovir	19-28	tegument serine/threonine protein kinase	Human betaherpesvirus 5	88-92
9408606-1	1997	We previously reported that the recombinant adenovirus (Ad) vector containing the thymidine kinase (TK) gene driven by the osteocalcin (OC) promoter (Ad-OC-TK), when delivered concurrently with acyclovir (ACV), is highly selective in blocking the growth of osteosarcoma in experimental models (Cancer Res.	Acyclovir	194-203	bone gamma-carboxyglutamate protein 2	Mus musculus	123-134
9436028-15	1997	We have obtained data to suggest that Ad-OC-TK plus a pro-drug acyclovir (ACV) may be used as an effective therapy to treat prostate cancer bone metastasis in models where the growth of androgen-independent PC-3 and C4-2 tumors in the bone has occurred.	Acyclovir	63-72	CDK5 regulatory subunit associated protein 1	Homo sapiens	216-220
9436028-15	1997	We have obtained data to suggest that Ad-OC-TK plus a pro-drug acyclovir (ACV) may be used as an effective therapy to treat prostate cancer bone metastasis in models where the growth of androgen-independent PC-3 and C4-2 tumors in the bone has occurred.	Acyclovir	74-77	CDK5 regulatory subunit associated protein 1	Homo sapiens	216-220
7565681-1	1995	Dividing eukaryotic cells expressing the herpes simplex virus type 1 thymidine kinase (TK) gene are sensitive to the cytotoxic effect of nucleoside analogs such as acyclovir or ganciclovir (GCV).	Acyclovir	164-173	involved in nucleotide metabolism	Human alphaherpesvirus 1	69-85
11322278-7	1997	After adjustment for CD4 cell count, the use of other antiretroviral agents, race, transmission risk and a history of herpesvirus infection, acyclovir use alone was independently associated with a relative hazard (RH) of death of 1.008 (P = 0.969); zidovudine use alone with a RH of 0.559 (P < 0.001); and combination use of acyclovir and zidovudine associated with a RH of 1.062 (P = 0.788).	Acyclovir	141-150	CD4 molecule	Homo sapiens	21-24
8869593-9	1996	A longer period of cell ablation induction (acyclovir 400 mg/kg per day, for 21 days) reduced not only pituitary but also plasma FSH concentrations (55 and 57% respectively; P < 0.05) without affecting LH.	Acyclovir	44-53	follicle stimulating hormone beta	Mus musculus	129-132
8869593-13	1996	Secondly, the FSH beta promoter directs the expression of tg tk in the pituitary gonadotrope cells, as shown by specific but partial ablation of FSH-producing cells after induction by gancyclovir and acyclovir.	Acyclovir	200-209	follicle stimulating hormone beta	Mus musculus	14-22
8869593-13	1996	Secondly, the FSH beta promoter directs the expression of tg tk in the pituitary gonadotrope cells, as shown by specific but partial ablation of FSH-producing cells after induction by gancyclovir and acyclovir.	Acyclovir	200-209	follicle stimulating hormone beta	Mus musculus	14-17
8683981-1	1996	Acyclovir (ACV), a nucleoside analog, has been demonstrated previously to suppress selectively the proliferation of NIH3T3 fibroblastic cells transformed by either v-abl or bcr-abl gene transfection.	Acyclovir	0-9	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	173-180
8683981-1	1996	Acyclovir (ACV), a nucleoside analog, has been demonstrated previously to suppress selectively the proliferation of NIH3T3 fibroblastic cells transformed by either v-abl or bcr-abl gene transfection.	Acyclovir	11-14	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	173-180
9116609-6	1997	Intravenous acyclovir (i.v./PCB) significantly reduced the risk of CMV infection when compared to the control group.	Acyclovir	12-21	pyruvate carboxylase	Homo sapiens	28-31
8906748-5	1996	Also, it was shown that addition of acyclovir, an inhibitor of the EBV-encoded DNA polymerase, to anti-IgG-stimulated Akata cells inhibited the productive replication of EBV DNA, but had no effect on the expression of early genes of the virus, including BZLF1, BRLF1, BMRF1, and BHRF1.	Acyclovir	36-45	protein Zta	Human gammaherpesvirus 4	254-259
8906748-5	1996	Also, it was shown that addition of acyclovir, an inhibitor of the EBV-encoded DNA polymerase, to anti-IgG-stimulated Akata cells inhibited the productive replication of EBV DNA, but had no effect on the expression of early genes of the virus, including BZLF1, BRLF1, BMRF1, and BHRF1.	Acyclovir	36-45	BRLF1	Human gammaherpesvirus 4	261-266
8906748-5	1996	Also, it was shown that addition of acyclovir, an inhibitor of the EBV-encoded DNA polymerase, to anti-IgG-stimulated Akata cells inhibited the productive replication of EBV DNA, but had no effect on the expression of early genes of the virus, including BZLF1, BRLF1, BMRF1, and BHRF1.	Acyclovir	36-45	BMRF1	Human gammaherpesvirus 4	268-273
8906748-5	1996	Also, it was shown that addition of acyclovir, an inhibitor of the EBV-encoded DNA polymerase, to anti-IgG-stimulated Akata cells inhibited the productive replication of EBV DNA, but had no effect on the expression of early genes of the virus, including BZLF1, BRLF1, BMRF1, and BHRF1.	Acyclovir	36-45	apoptosis regulator BHRF1	Human gammaherpesvirus 4	279-284
9024946-5	1996	Similarly, the in vivo exposure revealed selective T cell immunotoxicity of ACV and its derivatives since the reduced number of Thy 1.2+ and CD8+ cells was not accompanied with any marked changes in the Ig+ population.	Acyclovir	76-79	thymus cell antigen 1, theta	Mus musculus	128-135
8796890-4	1996	Furthermore, CD4+ T cells harboring the HSV-TK gene under the control of HIV regulatory sequences are protected from HIV spreading in the presence of acyclovir.	Acyclovir	150-159	CD4 molecule	Homo sapiens	13-16
7565681-1	1995	Dividing eukaryotic cells expressing the herpes simplex virus type 1 thymidine kinase (TK) gene are sensitive to the cytotoxic effect of nucleoside analogs such as acyclovir or ganciclovir (GCV).	Acyclovir	164-173	involved in nucleotide metabolism	Human alphaherpesvirus 1	87-89
7486956-4	1995	et Perry, or Terminalia chebula Retzus showed a stronger anti-HSV-1 activity in combination with acyclovir than the other herbal extracts in vitro.	Acyclovir	97-106	NDV-induced circulating interferon, X-linked	Mus musculus	62-67
7541712-6	1995	Moreover, the addition of dexamethasone increased the cytotoxicity of aciclovir to the virus-infected, AFP-producing cells through a glucocorticoid-responsive element in the AFP promoter, although aciclovir, by itself, had little cytotoxicity.	Acyclovir	70-79	alpha fetoprotein	Homo sapiens	103-106
7541712-6	1995	Moreover, the addition of dexamethasone increased the cytotoxicity of aciclovir to the virus-infected, AFP-producing cells through a glucocorticoid-responsive element in the AFP promoter, although aciclovir, by itself, had little cytotoxicity.	Acyclovir	70-79	alpha fetoprotein	Homo sapiens	174-177
7486956-8	1995	Combinations of acyclovir with historically used herbal medicines showed strong combined therapeutic anti-HSV-1 activity in mice, especially reduction of virus yield in the brain.	Acyclovir	16-25	NDV-induced circulating interferon, X-linked	Mus musculus	106-111
7603364-11	1995	The highest selectivity indexes were recorded for BV-araU > Pry-araU > acyclovir > or = penciclovir > AraA.	Acyclovir	77-86	PTPN13 like Y-linked	Homo sapiens	63-66
7779152-1	1995	The pharmacokinetics and bioavailability of aciclovir (CAS 59277-89-3) were examined after administration of newly developed 200 mg and 400 mg tablets.	Acyclovir	44-53	BCAR1 scaffold protein, Cas family member	Homo sapiens	55-58
7633946-4	1995	The rationale for this approach was that ACV and GCV are nucleoside analogs specifically converted by HSV1-TK to a toxic form capable of inhibiting DNA synthesis or disrupting cellular DNA replication.	Acyclovir	41-44	involved in nucleotide metabolism	Human alphaherpesvirus 1	107-109
7633946-5	1995	The results obtained from our experiments demonstrate that the retroviral vector-mediated HSV1-TK gene transfer leads to ACV- and GCV-dependent cytotoxicity in human lung cancer cell lines, including both small-cell carcinoma and non-small-cell carcinoma.	Acyclovir	121-124	involved in nucleotide metabolism	Human alphaherpesvirus 1	95-97
7758821-1	1995	Suppression of gonadotropins was induced by gancyclovir or acyclovir treatment in transgenic mice carrying 2.3 kb of bovine follicle-stimulating hormone beta (FSH beta) promoter fused to Herpes simplex virus thymidine kinase (tk) coding sequence.	Acyclovir	59-68	follitropin subunit beta	Bos taurus	159-167
8122378-1	1994	A detailed knowledge of the pathogenesis of infections caused by thymidine-kinase (TK)-deficient herpes simplex virus type 1 (HSV-1) strains is important because such mutants can arise during treatment of HSV infections with acyclovir--especially in immunocompromised patients--and also because TK-negative mutants may become useful for the therapy of intracranial tumors.	Acyclovir	225-234	involved in nucleotide metabolism	Human alphaherpesvirus 1	65-81
8106965-1	1994	Persons with AIDS who have CD4+ counts < or = 100 and transplant patients, especially bone marrow allograft recipients, may experience clinically significant infections with acyclovir-resistant herpes simplex virus (HSV) or varicella-zoster virus (VZV).	Acyclovir	177-186	CD4 molecule	Homo sapiens	27-30
7962265-0	1994	Standardisation of a microplate in situ ELISA (MISE-test) for the susceptibility testing of herpes simplex virus to acyclovir.	Acyclovir	116-125	INTS3 and NABP interacting protein	Homo sapiens	47-51
7855636-4	1994	Five mutants of VZV which were resistant to acyclovir (ACV), phosphonoacetic acid (PAA) or bromodeoxyuridine (BUDR) were also sensitive to IFN beta, their average ID50 being 1.31 IU/ml.	Acyclovir	55-58	interferon alpha 1	Homo sapiens	139-142
8027512-10	1994	In addition, various nucleoside analogs, including acyclovir and trifluridine as well as adenosine, guanosine and dibutyryl cyclic AMP, also potentiated the toxicity of ricin.	Acyclovir	51-60	ricin	Ricinus communis	169-174
8122378-1	1994	A detailed knowledge of the pathogenesis of infections caused by thymidine-kinase (TK)-deficient herpes simplex virus type 1 (HSV-1) strains is important because such mutants can arise during treatment of HSV infections with acyclovir--especially in immunocompromised patients--and also because TK-negative mutants may become useful for the therapy of intracranial tumors.	Acyclovir	225-234	involved in nucleotide metabolism	Human alphaherpesvirus 1	83-85
8389940-4	1993	Surprisingly, the NF-kappa B and HLP-1 binding activities were substantially inhibited in acyclovir-treated cells.	Acyclovir	90-99	nuclear factor kappa B subunit 1	Homo sapiens	18-28
8225157-2	1993	Initially, treatment with aciclovir (750 mg per day) improved CSF cell count and protein level.	Acyclovir	26-35	colony stimulating factor 2	Homo sapiens	62-65
8389940-4	1993	Surprisingly, the NF-kappa B and HLP-1 binding activities were substantially inhibited in acyclovir-treated cells.	Acyclovir	90-99	huntingtin associated protein 1	Homo sapiens	33-38
8380452-0	1993	Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS.	Acyclovir	44-53	thymidine kinase	Human alphaherpesvirus 3	16-32
8385896-0	1993	Inhibitors of thymidylate synthase and dihydrofolate reductase potentiate the antiviral effect of acyclovir.	Acyclovir	98-107	thymidylate synthetase	Homo sapiens	14-34
8385896-4	1993	Theoretically, agents which inhibit thymidylate synthase or dihydrofolate reductase should reduce intracellular pools of thymidine, resulting in the potentiation of the antiviral effects of acyclovir.	Acyclovir	190-199	thymidylate synthetase	Homo sapiens	36-56
8385896-7	1993	It is suggested that inhibitors of thymidylate synthase and dihydrofolate reductase warrant further exploration as potentiators of acyclovir.	Acyclovir	131-140	thymidylate synthetase	Homo sapiens	35-55
8380452-2	1993	The ACV resistance of isolates recovered from such patients is associated with diminished VZV thymidine kinase (TK) function.	Acyclovir	4-7	thymidine kinase	Human alphaherpesvirus 3	94-110
8380452-2	1993	The ACV resistance of isolates recovered from such patients is associated with diminished VZV thymidine kinase (TK) function.	Acyclovir	4-7	thymidine kinase	Human alphaherpesvirus 3	112-114
1331046-4	1992	The increased ACV triphosphate formation might be due to a higher level of 5"-nucleotidase, the enzyme responsible for trace levels of ACV phosphorylation in uninfected cells.	Acyclovir	14-17	5' nucleotidase, ecto	Mus musculus	75-90
8392160-1	1993	The nucleoside analog acyclovir is remarkably effective and selective in herpes simplex virus (HSF) infections.	Acyclovir	22-31	interleukin 6	Homo sapiens	95-98
8245894-1	1993	Zovirax (acyclovir, ACV) is now widely accepted as a safe and effective treatment for the management of herpes simplex virus (HSV) infections in normal and immunocompromised patients.	Acyclovir	0-7	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	20-23
1436296-8	1992	These results suggest that high doses of acyclovir produce azotemia and an abnormal function of the proximal tubule and thick ascending limb associated with resistance to vasopressin of the IMCD.	Acyclovir	41-50	arginine vasopressin	Rattus norvegicus	171-182
1329374-0	1992	A point mutation in the thymidine kinase gene is responsible for acyclovir-resistance in herpes simplex virus type 2 sequential isolates.	Acyclovir	65-74	involved in nucleotide metabolism	Human alphaherpesvirus 2	24-40
1329374-8	1992	Data presented confirm that a prolonged treatment with acyclovir can easily select ACV-r HSV-2 isolates carrying a TK- phenotype caused by a frameshift mutation.	Acyclovir	55-64	involved in nucleotide metabolism	Human alphaherpesvirus 2	115-117
2393279-10	1990	These data suggest that IFN-alpha-induced alterations in nucleoside metabolism may be one mechanism whereby IFN-alpha and acyclovir express synergistic antiherpes-virus activity.	Acyclovir	122-131	interferon alpha 1	Homo sapiens	24-33
1656355-2	1991	A significant variation in the growth of these isolates in BSC1 cells in the presence of 5-iodo-2"-deoxyuridine and acyclovir was observed.	Acyclovir	116-125	solute carrier family 12 member 1	Homo sapiens	59-63
1961215-3	1991	A 6.3-year-old girl was treated with acyclovir at day 10 of her illness, when cCT showed hemorrhagic necrosis in the brain.	Acyclovir	37-46	CCT	Homo sapiens	78-81
1650669-7	1991	These studies document that combinations of acyclic nucleoside analogs, ACV and DHPG, with IFN-alpha 2 resulted in synergistic anti-HSV activities in both Vero and human corneal stromal cells, while the pyrimidine analogs, TFT and BVdU, were not synergistic with IFN-alpha 2.	Acyclovir	72-75	interferon alpha 2	Homo sapiens	263-274
2177690-5	1990	Acyclovir therapy was administered under the diagnosis of HSE.	Acyclovir	0-9	hydroxysteroid 17-beta dehydrogenase 6	Homo sapiens	58-61
2365817-7	1990	Its expression is inhibited by cycloheximide or acyclovir, indicating this LAT is synthesized late in the viral replicative cycle.	Acyclovir	48-57	linker for activation of T cells	Homo sapiens	75-78
1777174-7	1991	Patients receiving zidovudine with or without acyclovir had moderate increases in CD4+ cell counts compared with placebo recipients and serum HIV p24 antigen level decreased significantly in all those receiving zidovudine.	Acyclovir	46-55	CD4 molecule	Homo sapiens	82-85
1906425-1	1991	beta 2-microglobulin levels were determined in the serum of 18 initially asymptomatic HIV-1 p24 antigenaemic subjects who were treated with zidovudine (+/- acyclovir) and who were followed for 2 1/2 years.	Acyclovir	156-165	beta-2-microglobulin	Homo sapiens	0-20
1650669-3	1991	Synergistic anti-HSV activity between IFN-alpha 2 and the acyclic guanosine analogs, acyclovir (ACV) and ganciclovir (DHPG), was demonstrated in cytopathic effect reduction assay in human corneal cell cultures as well as in Vero cells.	Acyclovir	85-94	interferon alpha 2	Homo sapiens	38-49
1650669-3	1991	Synergistic anti-HSV activity between IFN-alpha 2 and the acyclic guanosine analogs, acyclovir (ACV) and ganciclovir (DHPG), was demonstrated in cytopathic effect reduction assay in human corneal cell cultures as well as in Vero cells.	Acyclovir	96-99	interferon alpha 2	Homo sapiens	38-49
1650669-4	1991	In this assay system IFN-alpha 2 alone had little detectable antiviral activity at titers of greater than or equal to 2,000 IU/ml, however, treatment of cells with about 100 IU/ml of IFN-alpha 2 for 24 hrs prior to infection decreased the ED50 of ACV approximately 2- to 3-fold and of DHPG approximately 5- to 6-fold in Vero cells.	Acyclovir	247-250	interferon alpha 2	Homo sapiens	183-194
2153254-4	1990	The molar concentration of cystatin C that gave total inhibition of HSV replication was lower than that of either Z-LVG-CHN2 or of acyclovir, the drug currently most used against HSV infections.	Acyclovir	131-140	cystatin C	Homo sapiens	27-37
2387118-9	1990	Acyclovir (250 mg bid/day) was given for ten days.	Acyclovir	0-9	BH3 interacting domain death agonist	Homo sapiens	18-21
2179067-2	1990	Patients with recently healed duodenal ulcer were entered into a double blind, randomised study of maintenance treatment with the antiviral drug acyclovir (400 mg bid) versus placebo, to determine if suppression of herpes virus infection would influence the natural history of the ulcer disease.	Acyclovir	145-154	BH3 interacting domain death agonist	Homo sapiens	163-166
2163462-4	1990	In this study, the interaction between human fibroblast interferon (HuIFN-beta) and anti-herpetic agents, 5-iodo-2"-deoxyuridine (IDU), aciclovir (ACV) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), was studied in vitro using VERO cells.	Acyclovir	147-150	interferon beta 1	Homo sapiens	45-66
30121252-1	2018	Biphenyl hydrolase-like protein (BPHL) is a novel human serine hydrolase that was originally cloned from a breast carcinoma cDNA library and shown to convert valacyclovir to acyclovir and valganciclovir to ganciclovir.	Acyclovir	161-170	biphenyl hydrolase like	Homo sapiens	0-31
30121252-1	2018	Biphenyl hydrolase-like protein (BPHL) is a novel human serine hydrolase that was originally cloned from a breast carcinoma cDNA library and shown to convert valacyclovir to acyclovir and valganciclovir to ganciclovir.	Acyclovir	161-170	biphenyl hydrolase like	Homo sapiens	33-37
34678271-3	2022	In this study, the contribution of physiology (i.e., OCT1 activity) to the oral disposition of acyclovir immediate release (IR) tablets was hypothesized to be greater than dissolution.	Acyclovir	95-104	solute carrier family 22 member 1	Homo sapiens	53-57
34923092-4	2022	Cell cycle analysis revealed an increase of the sub-G1 hypodiploid peak after ACV treatment; the activation of caspase-3 and the presence of DNA laddering sustained the capacity of the drug to induce apoptotic cell death.	Acyclovir	78-81	caspase 3	Homo sapiens	111-120
34766503-5	2021	The p-terphenyl derivatives displayed inhibitory activities against HSV-1/2 with EC50 values ranging from 1.4 +- 0.6 to 9.3 +- 3.7 muM in Vero cells, which showed that they possessed antiviral activities with low cytotoxicity, superior to the current clinical drug acyclovir (EC50 3.6 +- 0.7 muM).	Acyclovir	265-274	hsv-1/2	None	68-75
34560144-0	2021	Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility.	Acyclovir	73-82	DNA polymerase catalytic subunit	Human betaherpesvirus 5	36-40
34831393-7	2021	AnxA1 expression was elevated among groups treated with PL or Ac2-26 + PL but reduced after treatment with Ac2-26.	Acyclovir	62-65	annexin A1	Rattus norvegicus	0-5
34831393-7	2021	AnxA1 expression was elevated among groups treated with PL or Ac2-26 + PL but reduced after treatment with Ac2-26.	Acyclovir	107-110	annexin A1	Rattus norvegicus	0-5
34738452-0	2021	(Antiviral activity of the organic germanium complex with aciclovir against herpes simplex virus (Herpesviridae: Alphaherpesvirinae: Simplexvirus: Human alphaherpesvirus 1/2) in the in vitro and in vivo systems).	Acyclovir	58-67	alphaherpesvirus 1/2	None	153-173
34560144-4	2021	The viral UL97 kinase phosphorylates acyclovir, and cross-resistance of ganciclovir-resistant mutants is documented.	Acyclovir	37-46	tegument serine/threonine protein kinase	Human betaherpesvirus 5	10-14
34560144-9	2021	Several foscarnet-resistant UL54 mutants outside the exonuclease domains, some with low-grade ganciclovir/cidofovir cross-resistance, showed various degrees of acyclovir resistance.	Acyclovir	160-169	DNA polymerase catalytic subunit	Human betaherpesvirus 5	28-32
34110440-8	2021	The limits of detection (LOD) of acyclovir, famciclovir, ganciclovir, penciclovir, and valaciclovir were 0.48 ng mL-1, 0.53 ng mL-1, 0.50 ng mL-1, 0.56 ng mL-1, and 0.38 ng mL-1, respectively.	Acyclovir	33-42	L1 cell adhesion molecule	Mus musculus	113-117
34847003-0	2021	Acyclovir-Resistant Cutaneous Herpes Simplex Virus in DOCK8 Deficiency.	Acyclovir	0-9	dedicator of cytokinesis 8	Homo sapiens	54-59
34531841-6	2021	Collectively, HT showed antiviral activity against HSV-1 and ACV-resistant strains by targeting HVEM and could be a promising therapeutic candidate for mitigating HSV-1-induced-pathogenesis.	Acyclovir	61-64	TNF receptor superfamily member 14	Homo sapiens	96-100
34110440-8	2021	The limits of detection (LOD) of acyclovir, famciclovir, ganciclovir, penciclovir, and valaciclovir were 0.48 ng mL-1, 0.53 ng mL-1, 0.50 ng mL-1, 0.56 ng mL-1, and 0.38 ng mL-1, respectively.	Acyclovir	33-42	L1 cell adhesion molecule	Mus musculus	173-177
34555435-5	2021	Further, we observed a markedly reduced expression levels of WSSV genes (immediately early IE gene ie1, DNA polymerase gene DNApol and envelope protein gene Vp28) that are crucial in viral life cycle with the acyclovir treatment during the early infection.	Acyclovir	209-218	endogenous retrovirus group K member 6, envelope	Homo sapiens	135-151
34234136-0	2021	NUDT15 polymorphism influences the metabolism and therapeutic effects of acyclovir and ganciclovir.	Acyclovir	73-82	nudix hydrolase 15	Homo sapiens	0-6
34255603-4	2021	In our case, a DOCK8-deficient patient with chalazia and conjunctivitis resistant to antibiotics, steroids and debulking responded to intravenous acyclovir.	Acyclovir	146-155	dedicator of cytokinesis 8	Homo sapiens	15-20
34234136-3	2021	Profiling NNA drugs, we identify acyclovir (ACV) and ganciclovir (GCV) as two new NNAs metabolized by NUDT15.	Acyclovir	33-42	nudix hydrolase 15	Homo sapiens	102-108
34234136-3	2021	Profiling NNA drugs, we identify acyclovir (ACV) and ganciclovir (GCV) as two new NNAs metabolized by NUDT15.	Acyclovir	44-47	nudix hydrolase 15	Homo sapiens	102-108
34234136-5	2021	Loss of NUDT15 potentiates cytotoxicity of ACV and GCV in host cells.	Acyclovir	43-46	nudix hydrolase 15	Homo sapiens	8-14
34234136-8	2021	In conclusion, NUDT15 is an important metabolizing enzyme for ACV and GCV, and NUDT15 variation contributes to inter-patient variability in their therapeutic effects.	Acyclovir	62-65	nudix hydrolase 15	Homo sapiens	15-21
35530033-6	2022	In the present study strategically, we performed the blind molecular docking of antiviral drug (Abacavir, Acyclovir, and Galidesivir)-choline based ILs conjugates with the target protein (Mpro protease).	Acyclovir	106-115	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	188-192
35185822-3	2021	Interestingly, Hsp90 inhibitors also reduced virus titers of ACV-resistant clinical HSV-1 strains (153 and blue strain), revealing that HSV-1 UL42 would be a new target against ACV-resistant HSV-1 strains.	Acyclovir	61-64	DNA polymerase processivity subunit	Human alphaherpesvirus 1	142-146
35271913-2	2022	In the majority of cases, HSV-2 resistance to ACV is due to amino acid changes within the viral thymidine kinase (TK).	Acyclovir	46-49	involved in nucleotide metabolism	Human alphaherpesvirus 2	96-112
35508593-3	2022	METHODS: Physiologically based pharmacokinetic models were constructed for four OAT1/3 substrates in healthy individuals: acyclovir, meropenem, furosemide, and ciprofloxacin.	Acyclovir	122-131	solute carrier family 22 member 6	Homo sapiens	80-86
35112329-0	2022	Acyclovir Brain Disposition: Interactions with P-gp, Bcrp, Mrp2, and Oat3 at the Blood-Brain Barrier.	Acyclovir	0-9	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	47-51
35112329-0	2022	Acyclovir Brain Disposition: Interactions with P-gp, Bcrp, Mrp2, and Oat3 at the Blood-Brain Barrier.	Acyclovir	0-9	ATP binding cassette subfamily B member 4	Rattus norvegicus	59-63
35112329-0	2022	Acyclovir Brain Disposition: Interactions with P-gp, Bcrp, Mrp2, and Oat3 at the Blood-Brain Barrier.	Acyclovir	0-9	solute carrier family 22 member 8	Rattus norvegicus	69-73
35112329-2	2022	The purpose of this study was to investigate the interactions between acyclovir and the efflux pumps P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), multidrug resistance protein 2 (Mrp2), and organic anion transporter 3 (Oat3) at the blood-brain barrier (BBB).	Acyclovir	70-79	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	101-115
35112329-2	2022	The purpose of this study was to investigate the interactions between acyclovir and the efflux pumps P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), multidrug resistance protein 2 (Mrp2), and organic anion transporter 3 (Oat3) at the blood-brain barrier (BBB).	Acyclovir	70-79	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	117-121
35112329-2	2022	The purpose of this study was to investigate the interactions between acyclovir and the efflux pumps P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), multidrug resistance protein 2 (Mrp2), and organic anion transporter 3 (Oat3) at the blood-brain barrier (BBB).	Acyclovir	70-79	ATP binding cassette subfamily B member 4	Rattus norvegicus	165-195
35112329-2	2022	The purpose of this study was to investigate the interactions between acyclovir and the efflux pumps P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), multidrug resistance protein 2 (Mrp2), and organic anion transporter 3 (Oat3) at the blood-brain barrier (BBB).	Acyclovir	70-79	ATP binding cassette subfamily B member 4	Rattus norvegicus	197-201
35112329-2	2022	The purpose of this study was to investigate the interactions between acyclovir and the efflux pumps P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), multidrug resistance protein 2 (Mrp2), and organic anion transporter 3 (Oat3) at the blood-brain barrier (BBB).	Acyclovir	70-79	solute carrier family 22 member 8	Rattus norvegicus	208-235
35112329-2	2022	The purpose of this study was to investigate the interactions between acyclovir and the efflux pumps P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), multidrug resistance protein 2 (Mrp2), and organic anion transporter 3 (Oat3) at the blood-brain barrier (BBB).	Acyclovir	70-79	solute carrier family 22 member 8	Rattus norvegicus	237-241
35112329-9	2022	CONCLUSION: The present study demonstrated that P-gp, Bcrp, Mrp2, and Oat3 inhibition increased the penetration of acyclovir across the BBB, supporting the hypothesis that these efflux pumps restrict the distribution of acyclovir in the brain.	Acyclovir	115-124	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	48-52
35112329-9	2022	CONCLUSION: The present study demonstrated that P-gp, Bcrp, Mrp2, and Oat3 inhibition increased the penetration of acyclovir across the BBB, supporting the hypothesis that these efflux pumps restrict the distribution of acyclovir in the brain.	Acyclovir	115-124	ATP binding cassette subfamily B member 4	Rattus norvegicus	60-64
35112329-9	2022	CONCLUSION: The present study demonstrated that P-gp, Bcrp, Mrp2, and Oat3 inhibition increased the penetration of acyclovir across the BBB, supporting the hypothesis that these efflux pumps restrict the distribution of acyclovir in the brain.	Acyclovir	115-124	solute carrier family 22 member 8	Rattus norvegicus	70-74
35112329-9	2022	CONCLUSION: The present study demonstrated that P-gp, Bcrp, Mrp2, and Oat3 inhibition increased the penetration of acyclovir across the BBB, supporting the hypothesis that these efflux pumps restrict the distribution of acyclovir in the brain.	Acyclovir	220-229	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	48-52
35112329-9	2022	CONCLUSION: The present study demonstrated that P-gp, Bcrp, Mrp2, and Oat3 inhibition increased the penetration of acyclovir across the BBB, supporting the hypothesis that these efflux pumps restrict the distribution of acyclovir in the brain.	Acyclovir	220-229	solute carrier family 22 member 8	Rattus norvegicus	70-74
35185822-3	2021	Interestingly, Hsp90 inhibitors also reduced virus titers of ACV-resistant clinical HSV-1 strains (153 and blue strain), revealing that HSV-1 UL42 would be a new target against ACV-resistant HSV-1 strains.	Acyclovir	177-180	DNA polymerase processivity subunit	Human alphaherpesvirus 1	142-146
2554768-7	1989	The 3.3-kbp BamHI fragment containing most of the DNA polymerase gene from isolate 615.8 was purified and used to successfully transfer both acyclovir and foscarnet resistance.	Acyclovir	141-150	kinesin family binding protein	Homo sapiens	8-11
2512812-0	1989	Exogenous lactase in the treatment of oral acyclovir intolerance.	Acyclovir	43-52	lactase	Homo sapiens	10-17
2709690-3	1989	During treatment with Acyclovir the bleeding situation was controlled by fibrinogen replacement.	Acyclovir	22-31	fibrinogen beta chain	Homo sapiens	73-83
2554611-0	1989	Acyclovir resistance in herpes simplex virus type 1: biochemical and functional studies on the thymidine kinase of the highly resistant R100 strain.	Acyclovir	0-9	involved in nucleotide metabolism	Human alphaherpesvirus 1	95-111
2554611-1	1989	The biochemical and functional properties of the thymidine kinase (TK) of the herpes simplex virus type 1 mutant R100, that is highly resistant to 9-(2-hydroxyethoxymethyl)guanine (acyclovir), are reported in comparison with the properties of its parental strain, wt.	Acyclovir	147-179	involved in nucleotide metabolism	Human alphaherpesvirus 1	49-65
2554611-1	1989	The biochemical and functional properties of the thymidine kinase (TK) of the herpes simplex virus type 1 mutant R100, that is highly resistant to 9-(2-hydroxyethoxymethyl)guanine (acyclovir), are reported in comparison with the properties of its parental strain, wt.	Acyclovir	147-179	involved in nucleotide metabolism	Human alphaherpesvirus 1	67-69
2554611-1	1989	The biochemical and functional properties of the thymidine kinase (TK) of the herpes simplex virus type 1 mutant R100, that is highly resistant to 9-(2-hydroxyethoxymethyl)guanine (acyclovir), are reported in comparison with the properties of its parental strain, wt.	Acyclovir	181-190	involved in nucleotide metabolism	Human alphaherpesvirus 1	49-65
2554611-1	1989	The biochemical and functional properties of the thymidine kinase (TK) of the herpes simplex virus type 1 mutant R100, that is highly resistant to 9-(2-hydroxyethoxymethyl)guanine (acyclovir), are reported in comparison with the properties of its parental strain, wt.	Acyclovir	181-190	involved in nucleotide metabolism	Human alphaherpesvirus 1	67-69
2542442-0	1989	Altered in vitro uptake of the radiolabelled antiviral imaging "probe" E-5-(2-125iodovinyl)-2"-deoxyuridine following administration of acyclovir.	Acyclovir	136-145	Rho guanine nucleotide exchange factor 15	Homo sapiens	71-74
2844967-3	1988	Acyclovir-resistant strains expressed the 1.8 kb VZV dPK transcript but lacked dPK activity.	Acyclovir	0-9	parkin	Drosophila melanogaster	53-56
2904885-5	1988	Both T cell-depleted blood mononuclear cells and the EBV-transformed B cell line (treated with Acyclovir to block endogenous gp340 production) could be used for presentation, the latter being the more efficient when gp340 iscoms was the source of antigen.	Acyclovir	95-104	deleted in malignant brain tumors 1	Homo sapiens	125-130
2844967-3	1988	Acyclovir-resistant strains expressed the 1.8 kb VZV dPK transcript but lacked dPK activity.	Acyclovir	0-9	parkin	Drosophila melanogaster	79-82
2844967-7	1988	The dPK genes from the acyclovir-resistant strains contained either point mutations near the putative thymidine-binding site of the enzyme or ones that resulted in the premature termination of protein synthesis.	Acyclovir	23-32	parkin	Drosophila melanogaster	4-7
2844967-8	1988	Single point mutations were sufficient to render these strains dPK-negative and highly resistant to acyclovir.	Acyclovir	100-109	parkin	Drosophila melanogaster	63-66
2844967-9	1988	The molecular basis for acyclovir resistance at the dPK locus of VZV is similar to that previously noted to render herpes simplex viruses resistant to acyclovir.	Acyclovir	24-33	parkin	Drosophila melanogaster	52-55
2844967-9	1988	The molecular basis for acyclovir resistance at the dPK locus of VZV is similar to that previously noted to render herpes simplex viruses resistant to acyclovir.	Acyclovir	151-160	parkin	Drosophila melanogaster	52-55
2835427-5	1988	Levels of antibodies to individual proteins were also lower in sera from acyclovir versus placebo treated patients: gB (P = 0.013), gC/gE (P = 0.017), VP16 (P = 0.001), gD (P = 0.009), and p45 (P = 0.015).	Acyclovir	73-82	host cell factor C1	Homo sapiens	151-155
2835427-5	1988	Levels of antibodies to individual proteins were also lower in sera from acyclovir versus placebo treated patients: gB (P = 0.013), gC/gE (P = 0.017), VP16 (P = 0.001), gD (P = 0.009), and p45 (P = 0.015).	Acyclovir	73-82	nuclear factor, erythroid 2	Homo sapiens	189-192
2826804-2	1988	Treatment with acyclovir for the first 7 days after viral inoculation prevented lytic infections in 100% of the cultures and resulted in viral latency in 100% of the cultures; reactivation occurred as the result of nerve growth factor (NGF) deprivation.	Acyclovir	15-24	nerve growth factor	Homo sapiens	236-239
2820987-10	1987	The CD50 values of the free and target-sensitive immunoliposome-encapsulated ACV were 12.5 ng/ml and 1.4 micrograms/ml, respectively, whereas the ED50 values of the free and target-sensitive immunoliposome-encapsulated ACV were 1.1 and 125 ng/ml, respectively.	Acyclovir	77-80	intercellular adhesion molecule 5, telencephalin	Mus musculus	4-8
3598156-7	1986	Combination therapy with ACV may be more effective than IFN alone and is well tolerated.	Acyclovir	25-28	interferon alpha 1	Homo sapiens	56-59
2829709-0	1987	Nucleotide sequence changes in thymidine kinase gene of herpes simplex virus type 2 clones from an isolate of a patient treated with acyclovir.	Acyclovir	133-142	involved in nucleotide metabolism	Human alphaherpesvirus 2	31-47
2829709-1	1987	To identify the nucleotide changes that occur in drug-induced thymidine kinase (TK) mutants of herpes simplex virus type 2 (HSV-2), we compared the nucleotide sequences of the tk genes of two mutant HSV-2 clones isolated from a patient who had been treated with acyclovir [9-(2-hydroxyethoxymethyl)guanine; ACV] with the nucleotide sequence of the parental TK+ HSV-2(8703) strain isolated from the same patient.	Acyclovir	262-271	involved in nucleotide metabolism	Human alphaherpesvirus 2	80-82
2829709-1	1987	To identify the nucleotide changes that occur in drug-induced thymidine kinase (TK) mutants of herpes simplex virus type 2 (HSV-2), we compared the nucleotide sequences of the tk genes of two mutant HSV-2 clones isolated from a patient who had been treated with acyclovir [9-(2-hydroxyethoxymethyl)guanine; ACV] with the nucleotide sequence of the parental TK+ HSV-2(8703) strain isolated from the same patient.	Acyclovir	273-305	involved in nucleotide metabolism	Human alphaherpesvirus 2	80-82
2829709-1	1987	To identify the nucleotide changes that occur in drug-induced thymidine kinase (TK) mutants of herpes simplex virus type 2 (HSV-2), we compared the nucleotide sequences of the tk genes of two mutant HSV-2 clones isolated from a patient who had been treated with acyclovir [9-(2-hydroxyethoxymethyl)guanine; ACV] with the nucleotide sequence of the parental TK+ HSV-2(8703) strain isolated from the same patient.	Acyclovir	307-310	involved in nucleotide metabolism	Human alphaherpesvirus 2	80-82
3039009-0	1987	Antibody response to herpes simplex virus glycoprotein D: effects of acyclovir and relation to recurrence.	Acyclovir	69-78	atypical chemokine receptor 1 (Duffy blood group)	Homo sapiens	42-56
3039009-4	1987	Therapy with acyclovir delayed and diminished the antibody response to gD, although by day 60 the titers of antibody to gD in acyclovir-treated animals were not significantly different from those in controls.	Acyclovir	13-22	atypical chemokine receptor 1 (Duffy blood group)	Homo sapiens	71-73
3039009-4	1987	Therapy with acyclovir delayed and diminished the antibody response to gD, although by day 60 the titers of antibody to gD in acyclovir-treated animals were not significantly different from those in controls.	Acyclovir	13-22	atypical chemokine receptor 1 (Duffy blood group)	Homo sapiens	120-122
3039009-4	1987	Therapy with acyclovir delayed and diminished the antibody response to gD, although by day 60 the titers of antibody to gD in acyclovir-treated animals were not significantly different from those in controls.	Acyclovir	126-135	atypical chemokine receptor 1 (Duffy blood group)	Homo sapiens	120-122
3598156-3	1986	Combination of IFN and intravenous acyclovir (ACV, 15 mg/kg twice daily) led to a significantly greater fall in DNA-p and HBeAg, while tolerance of the combination therapy was excellent.	Acyclovir	46-49	interferon alpha 1	Homo sapiens	15-18
2991214-0	1985	Cytoplasmic 5"-nucleotidase catalyzes acyclovir phosphorylation.	Acyclovir	38-47	5' nucleotidase, ecto	Rattus norvegicus	12-27
2991214-6	1985	In addition, the pH optimum, ATP stimulation, and phosphate inhibition of the ACV phosphorylating activity paralleled those of the 5"-nucleotidase.	Acyclovir	78-81	5' nucleotidase, ecto	Rattus norvegicus	131-146
2982353-8	1985	In contrast to TK and dCK, only dGK is inhibited by Acyclovir (Ki = 320 microM).	Acyclovir	52-61	Diacyl glycerol kinase	Drosophila melanogaster	32-35
2983088-0	1985	Inhibition of cellular DNA polymerase alpha and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine.	Acyclovir	117-149	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	23-43
2983088-1	1985	The triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine were examined for their inhibitory effect on highly purified cellular DNA polymerase alpha and human cytomegalovirus (Towne strain)-induced DNA polymerase.	Acyclovir	21-53	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	169-189
2982353-9	1985	It is suggested that RCMV inducable dGK is an important enzyme determining the in vitro anti-CMV activity of Acyclovir.	Acyclovir	109-118	Diacyl glycerol kinase	Drosophila melanogaster	36-39
7102704-5	1982	The overall mean acyclovir plasma half-life and total body clearance +/- SD were 2.1 +/- 0.5 hours and 297 +/- 53 ml/min/1.73 m2.	Acyclovir	17-26	CD59 molecule (CD59 blood group)	Homo sapiens	117-122
6639669-0	1983	Effects of acyclovir and its metabolites on hypoxanthine-guanine phosphoribosyltransferase.	Acyclovir	11-20	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	44-90
6639669-1	1983	Acyclovir [9-(2-hydroxyethoxymethyl)guanine], a clinically useful anti-herpesvirus agent, was a weak inhibitor (Ki = 190 microM) of hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) from human erythrocytes.	Acyclovir	0-9	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	132-178
6639669-1	1983	Acyclovir [9-(2-hydroxyethoxymethyl)guanine], a clinically useful anti-herpesvirus agent, was a weak inhibitor (Ki = 190 microM) of hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) from human erythrocytes.	Acyclovir	0-9	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	180-188
6639669-1	1983	Acyclovir [9-(2-hydroxyethoxymethyl)guanine], a clinically useful anti-herpesvirus agent, was a weak inhibitor (Ki = 190 microM) of hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) from human erythrocytes.	Acyclovir	11-43	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	132-178
6355048-8	1983	Acyclovir half-life (T1/2 beta) and total body clearance (Cltot) are influenced significantly by renal function, and dosage adjustments should be made for patients with impaired renal function.	Acyclovir	0-9	interleukin 1 receptor like 1	Homo sapiens	21-30
6639669-1	1983	Acyclovir [9-(2-hydroxyethoxymethyl)guanine], a clinically useful anti-herpesvirus agent, was a weak inhibitor (Ki = 190 microM) of hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) from human erythrocytes.	Acyclovir	11-43	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	180-188
6351865-0	1983	Conversion of 2,6-diamino-9-(2-hydroxyethoxymethyl)purine to acyclovir as catalyzed by adenosine deaminase.	Acyclovir	61-70	adenosine deaminase	Homo sapiens	87-106
6296278-5	1982	5-Bromo-2"-deoxyuridine, 5-bromo-2"-deoxycytidine and 9-(2-hydroxyethoxymethyl)guanine were used to reduce the background of TK+ virus in heterogeneous recombinant stocks analysed for the presence of TK- recombinants.	Acyclovir	54-86	involved in nucleotide metabolism	Human alphaherpesvirus 1	125-127
230783-2	1979	Seventeen clinical isolates of HSV-1 were inhibited by ACG at a mean 50% inhibitory dose (ID(50)) of 0.15 +/- 0.09 muM.	Acyclovir	55-58	latexin	Homo sapiens	115-118
6285713-3	1982	The mean half-life (t 1/2 beta) of acyclovir was 3.78 +/- 1.21 hours.	Acyclovir	35-44	interleukin 1 receptor like 1	Homo sapiens	20-30
230783-5	1979	ACG at a concentration of 200 muM had no effect on deoxyribonucleic acid synthesis in human fibroblast cells and only inhibited thymidine incorporation by Vero cells by one-third.	Acyclovir	0-3	latexin	Homo sapiens	30-33
34010599-0	2021	Acyclovir induces fetal hemoglobin via down regulation of gamma-globin repressors, BCL11A and SOX6 trans-acting factors.	Acyclovir	0-9	BAF chromatin remodeling complex subunit BCL11A	Homo sapiens	83-89
34022892-12	2021	Furthermore, the interaction between Ac2-26 and FPR2/ALX receptor activated the 5" adenosine monophosphate-activated protein kinase (AMPK) and inhibited the downstream mammalian target of rapamycin (mTOR).	Acyclovir	37-40	formyl peptide receptor 2	Homo sapiens	48-52
34022892-12	2021	Furthermore, the interaction between Ac2-26 and FPR2/ALX receptor activated the 5" adenosine monophosphate-activated protein kinase (AMPK) and inhibited the downstream mammalian target of rapamycin (mTOR).	Acyclovir	37-40	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	133-137
34022892-12	2021	Furthermore, the interaction between Ac2-26 and FPR2/ALX receptor activated the 5" adenosine monophosphate-activated protein kinase (AMPK) and inhibited the downstream mammalian target of rapamycin (mTOR).	Acyclovir	37-40	mechanistic target of rapamycin kinase	Homo sapiens	168-197
34022892-12	2021	Furthermore, the interaction between Ac2-26 and FPR2/ALX receptor activated the 5" adenosine monophosphate-activated protein kinase (AMPK) and inhibited the downstream mammalian target of rapamycin (mTOR).	Acyclovir	37-40	mechanistic target of rapamycin kinase	Homo sapiens	199-203
34010599-0	2021	Acyclovir induces fetal hemoglobin via down regulation of gamma-globin repressors, BCL11A and SOX6 trans-acting factors.	Acyclovir	0-9	SRY-box transcription factor 6	Homo sapiens	94-98
34010599-7	2021	We found that acyclovir significantly induces expression of the gamma-globin gene and HbF synthesis in CD34+ erythroid progenitors, without affecting terminal erythroid differentiation and erythroid cell proliferation.	Acyclovir	14-23	CD34 antigen	Mus musculus	103-107
34010599-9	2021	Further, we reported the effect of acyclovir on gamma-globin gene transcriptional regulators including BCL11A, FOP1, KLF1 SOX6, and GATA-1.	Acyclovir	35-44	BAF chromatin remodeling complex subunit BCL11A	Homo sapiens	103-109
34010599-9	2021	Further, we reported the effect of acyclovir on gamma-globin gene transcriptional regulators including BCL11A, FOP1, KLF1 SOX6, and GATA-1.	Acyclovir	35-44	Kruppel like factor 1	Homo sapiens	117-121
34010599-9	2021	Further, we reported the effect of acyclovir on gamma-globin gene transcriptional regulators including BCL11A, FOP1, KLF1 SOX6, and GATA-1.	Acyclovir	35-44	SRY-box transcription factor 6	Homo sapiens	122-126
34010599-9	2021	Further, we reported the effect of acyclovir on gamma-globin gene transcriptional regulators including BCL11A, FOP1, KLF1 SOX6, and GATA-1.	Acyclovir	35-44	GATA binding protein 1	Mus musculus	132-138
34010599-11	2021	Whereas, GATA-1, a master erythroid transcription factor, was upregulated in acyclovir treated human CD34+ erythroid culture.	Acyclovir	77-86	GATA binding protein 1	Homo sapiens	9-15
34010599-11	2021	Whereas, GATA-1, a master erythroid transcription factor, was upregulated in acyclovir treated human CD34+ erythroid culture.	Acyclovir	77-86	CD34 molecule	Homo sapiens	101-105
33797314-3	2021	The retinitis responded to systemic acyclovir therapy and intravitreal ganciclovir.Conclusion: VZV retinitis can occur following CAR T-cell immunotherapy.	Acyclovir	36-45	nuclear receptor subfamily 1 group I member 3	Homo sapiens	129-132
33716051-3	2021	To contribute to this advancement, here we report on the ability of a new generation inhibitor of a key cellular enzyme of de novo pyrimidine biosynthesis, the dihydroorotate dehydrogenase (DHODH), to inhibit HSV-1 and HSV-2 in vitro replication, with a potency comparable to that of the reference drug acyclovir.	Acyclovir	303-312	dihydroorotate dehydrogenase (quinone)	Homo sapiens	190-195
33326128-4	2021	Acyclovir is indicated to minimize clinical manifestations with the suspected of viral association (HHV-6 and 7).	Acyclovir	0-9	hhv-6 and 7	None	100-111
33631413-0	2021	Efficient establishment of reactivatable latency by an acyclovir-resistant herpes simplex virus 1 thymidine kinase substitution mutant with reduced neuronal replication.	Acyclovir	55-64	involved in nucleotide metabolism	Human alphaherpesvirus 1	98-114
33476709-1	2021	MBX-2168 has a mechanism of action similar to that of acyclovir (ACV) and ganciclovir (GCV), but two unique steps differentiate this drug from ACV/GCV.	Acyclovir	143-146	diencephalon/mesencephalon homeobox 1	Homo sapiens	0-3
33253717-7	2021	Moreover, reverse transcript quantitative polymerase chain reaction (RT-qPCR) demonstrated that acyclovir suppressed the expression of caspase 3, caspase 8 and caspase 9, while there was no significant impact on the expression of the apoptosis-inhibiting gene bcl-2 in CCV-infected cells.	Acyclovir	96-105	caspase 3	Homo sapiens	135-144
33253717-7	2021	Moreover, reverse transcript quantitative polymerase chain reaction (RT-qPCR) demonstrated that acyclovir suppressed the expression of caspase 3, caspase 8 and caspase 9, while there was no significant impact on the expression of the apoptosis-inhibiting gene bcl-2 in CCV-infected cells.	Acyclovir	96-105	caspase 8	Homo sapiens	146-155
33253717-7	2021	Moreover, reverse transcript quantitative polymerase chain reaction (RT-qPCR) demonstrated that acyclovir suppressed the expression of caspase 3, caspase 8 and caspase 9, while there was no significant impact on the expression of the apoptosis-inhibiting gene bcl-2 in CCV-infected cells.	Acyclovir	96-105	caspase 9	Homo sapiens	160-169
33253717-7	2021	Moreover, reverse transcript quantitative polymerase chain reaction (RT-qPCR) demonstrated that acyclovir suppressed the expression of caspase 3, caspase 8 and caspase 9, while there was no significant impact on the expression of the apoptosis-inhibiting gene bcl-2 in CCV-infected cells.	Acyclovir	96-105	BCL2 apoptosis regulator	Homo sapiens	260-265
33326128-5	2021	Another group of the human herpesvirus family (HHV-1 and 2), causes herpes simplex that is controlled with the antivirals, including acyclovir, as well as the amino acid L-Lysine, both showing positive and similar results in reducing the number of annual manifestations and the healing time of the lesions.	Acyclovir	133-142	hhv-1 and 2	None	47-58
33322225-0	2020	Herpes Simplex Virus Type 1 Clinical Isolates Respond to UL29-Targeted siRNA Swarm Treatment Independent of Their Acyclovir Sensitivity.	Acyclovir	114-123	single-stranded DNA-binding protein	Human alphaherpesvirus 1	57-61
33390306-11	2021	Combined effects of EGCG and ACV were more evident for the expression of viral thymidine kinase, ICP5 and glycoprotein D.	Acyclovir	29-32	atypical chemokine receptor 1 (Duffy blood group)	Homo sapiens	106-120
33520534-8	2020	Soon after the start of acyclovir for HSV-2 infection, the genital pain and ulceration improved and platelet counts gradually increased to 157,000/muL.	Acyclovir	24-33	tripartite motif containing 37	Homo sapiens	147-150
33375004-9	2020	In contrast, mMate2 did not transport TCl but showed MPP+ transport with Km of 60.0 microM that was inhibited by the drugs topotecan, acyclovir, and levofloxacin.	Acyclovir	134-143	solute carrier family 47, member 2	Mus musculus	13-19
33322225-8	2020	Additionally, we showed that an acyclovir-resistant HSV-1, devoid of thymidine kinase, is highly sensitive to UL29 siRNA treatment (IC50 1.0 nM; Imax 97%).	Acyclovir	32-41	single-stranded DNA-binding protein	Human alphaherpesvirus 1	110-114
33155234-0	2020	Observation of the efficacy of naloxone combined with acyclovir in the treatment of children viral encephalitis and its impacts on IL-1 and IL-6.	Acyclovir	54-63	interleukin 1 alpha	Homo sapiens	131-135
32677551-9	2020	All 3 were treated with intravenous acyclovir, with complete recovery.	Acyclovir	36-45	paired box 5	Homo sapiens	0-5
33155234-0	2020	Observation of the efficacy of naloxone combined with acyclovir in the treatment of children viral encephalitis and its impacts on IL-1 and IL-6.	Acyclovir	54-63	interleukin 6	Homo sapiens	140-144
33155234-13	2020	CONCLUSIONS: In the treatment of children, viral encephalitis has naloxone combined with ganciclovir had a more significant effect on the decrease of levels of serum IL-1 and IL-6; naloxone combined with acyclovir in the treatment of children viral encephalitis had better effects, lower adverse reactions and lower prevalence of sequelae compared with sole medication, which is worth clinical promotion.	Acyclovir	204-213	interleukin 1 alpha	Homo sapiens	166-170
33155234-13	2020	CONCLUSIONS: In the treatment of children, viral encephalitis has naloxone combined with ganciclovir had a more significant effect on the decrease of levels of serum IL-1 and IL-6; naloxone combined with acyclovir in the treatment of children viral encephalitis had better effects, lower adverse reactions and lower prevalence of sequelae compared with sole medication, which is worth clinical promotion.	Acyclovir	204-213	interleukin 6	Homo sapiens	175-179
33134244-0	2020	Electrochemical Oxidation and Determination of Antiviral Drug Acyclovir by Modified Carbon Paste Electrode With Magnetic CdO Nanoparticles.	Acyclovir	62-71	cell adhesion associated, oncogene regulated	Homo sapiens	121-124
32659406-4	2020	In this study, acyclovir glutarate (AG), a prodrug of acyclovir, was synthesized to improve intestinal permeability by targeting monocarboxylate transporter 1 (MCT 1), an intestinal influx transporter.	Acyclovir	15-24	solute carrier family 16 member 1	Homo sapiens	129-158
32659406-4	2020	In this study, acyclovir glutarate (AG), a prodrug of acyclovir, was synthesized to improve intestinal permeability by targeting monocarboxylate transporter 1 (MCT 1), an intestinal influx transporter.	Acyclovir	15-24	solute carrier family 16 member 1	Homo sapiens	160-165
32659406-6	2020	AG was demonstrated to exhibit greatly higher cellular uptake efficiency and permeability than acyclovir due to the MCT 1-mediated active transport.	Acyclovir	95-104	solute carrier family 16 member 1	Homo sapiens	116-121
32659406-9	2020	Collectively, these results confirmed that nanonized MCT 1-targeted prodrugs enhanced the oral bioavailability of acyclovir in a cascade manner.	Acyclovir	114-123	solute carrier family 16 member 1	Homo sapiens	53-58
33134244-2	2020	In this study, a sensor was developed for the electrochemical determination of Acyclovir (ACV) based on the modified carbon paste electrode (CPE) by CdO/Fe3O4.	Acyclovir	79-88	cell adhesion associated, oncogene regulated	Homo sapiens	149-152
33134244-2	2020	In this study, a sensor was developed for the electrochemical determination of Acyclovir (ACV) based on the modified carbon paste electrode (CPE) by CdO/Fe3O4.	Acyclovir	90-93	cell adhesion associated, oncogene regulated	Homo sapiens	149-152
32221697-5	2020	In this study, we have found that the combination of acyclovir and DXMT, but not acyclovir or DXMT alone, could protect against AD causing beta-amyloid (Abeta) oligomer-induced spatial cognitive impairments.	Acyclovir	53-62	amyloid beta (A4) precursor protein	Mus musculus	153-158
32933625-1	2020	OBJECTIVE: To study the clinical effect of recombinant human interferon alpha1b assisting acyclovir on immune function, inflammatory factors, and myocardial zymogram in children with infectious mononucleosis (IM).	Acyclovir	90-99	interferon alpha 1	Homo sapiens	61-79
32933625-9	2020	CONCLUSIONS: For children with IM, recombinant human interferon alpha1b assisting acyclovir can effectively improve immune function, inhibit inflammatory reaction, reduce myocardial injury, and thus alleviate clinical symptoms.	Acyclovir	82-91	interferon alpha 1	Homo sapiens	53-71
32346764-5	2020	It has been previously reported by our research group that two new semisynthetic cardenolides, namely C10 (3beta-[(N-(2-hydroxyethyl)aminoacetyl]amino-3-deoxydigitoxigenin) and C11 (3beta-(hydroxyacetyl)amino-3-deoxydigitoxigenin), exhibited potential anti-HSV-1 and anti-HSV-2 with selectivity index values > 1,000, comparable with those of acyclovir.	Acyclovir	342-351	homeobox C10	Homo sapiens	102-105
32346764-9	2020	Both compounds inhibited HSV replication at nanomolar concentrations, but cardenolide C10 was more active than C11 and can be considered as an anti-herpes drug candidate including against acyclovir-resistant HSV-1 strains.	Acyclovir	188-197	homeobox C10	Homo sapiens	86-89
32221697-6	2020	Moreover, acyclovir and DXMT could prevent Abeta oligomer-induced over-activation of microglia and astrocytes, and over-expression of pro-inflammatory cytokines, indicating that anti-AD effects of drug combination might be at least partially via neuroinflammation inhibition and immunomodulation.	Acyclovir	10-19	amyloid beta (A4) precursor protein	Mus musculus	43-48
32221697-7	2020	Furthermore, Abeta oligomer-induced decrease of PSD-95 and increase of pTau expression was prevented by the combination of acyclovir and DXMT, suggesting the involvement of synaptic protective effects of the drug combination.	Acyclovir	123-132	amyloid beta (A4) precursor protein	Mus musculus	13-18
32221697-7	2020	Furthermore, Abeta oligomer-induced decrease of PSD-95 and increase of pTau expression was prevented by the combination of acyclovir and DXMT, suggesting the involvement of synaptic protective effects of the drug combination.	Acyclovir	123-132	discs large MAGUK scaffold protein 4	Mus musculus	48-54
31968222-7	2020	HSV-1-infected cells incubated with five times the EC50 of MBX-2168 (33.5 muM) or ACV (5.0 muM) demonstrated a time-dependent increase in triphosphate levels reaching a maximum of 12.3 +- 1.5 and 11.6 +- 0.7 pmol/106 cells at 24 h, respectively.	Acyclovir	82-85	latexin	Homo sapiens	91-94
32037154-8	2020	Cox regression analysis identified having confirmed herpes simplex virus disease (OR, 4.35; P = .002), receipt of >=2 concomitant nephrotoxic medications (OR, 3.07; P = .004), receipt of mechanical ventilation (OR, 5.97; P = .001), and admission to an intensive care unit (OR, 6.02; P = .006) as risk factors for AKI during acyclovir treatment.	Acyclovir	324-333	cytochrome c oxidase subunit 8A	Homo sapiens	0-3
31341258-0	2020	Leflunomide increased the renal exposure of acyclovir by inhibiting OAT1/3 and MRP2.	Acyclovir	44-53	solute carrier family 22 member 6	Homo sapiens	68-74
31756271-2	2020	Chromatographic separation of acyclovir and lidocaine was achieved using a reversed-phase C18 column and a gradient mobile phase (20 mm ammonium acetate pH 3.5 in water and acetonitrile).	Acyclovir	30-39	Bardet-Biedl syndrome 9	Homo sapiens	90-93
31278537-1	2020	We report a case of classic HSE with early neurological relapse 7 days after onset of acyclovir treatment secondary to cerebral venous thrombosis (CVT).	Acyclovir	86-95	hydroxysteroid 17-beta dehydrogenase 6	Homo sapiens	28-31
31341258-0	2020	Leflunomide increased the renal exposure of acyclovir by inhibiting OAT1/3 and MRP2.	Acyclovir	44-53	ATP binding cassette subfamily C member 2	Homo sapiens	79-83
31341258-2	2020	Acyclovir is a substrate of organic anion transporter (OAT) 1/3 and multidrug resistance-associated protein (MRP) 2.	Acyclovir	0-9	solute carrier family 22 member 6	Homo sapiens	28-63
31341258-2	2020	Acyclovir is a substrate of organic anion transporter (OAT) 1/3 and multidrug resistance-associated protein (MRP) 2.	Acyclovir	0-9	ATP binding cassette subfamily C member 2	Homo sapiens	68-115
31341258-4	2020	Here we used a specific MRP inhibitor MK571 and probenecid (OAT1/3 and MRP2 inhibitor) to assess the effects of MRP2 and OAT1/3 on the pharmacokinetics and tissue distribution of acyclovir in rats.	Acyclovir	179-188	ATP binding cassette subfamily C member 2	Rattus norvegicus	112-116
31341258-4	2020	Here we used a specific MRP inhibitor MK571 and probenecid (OAT1/3 and MRP2 inhibitor) to assess the effects of MRP2 and OAT1/3 on the pharmacokinetics and tissue distribution of acyclovir in rats.	Acyclovir	179-188	solute carrier family 22 member 6	Rattus norvegicus	121-127
31341258-10	2020	TER (5 mumol/L) significantly inhibited the uptake of acyclovir in hOAT1/3-HEK293 cells.	Acyclovir	54-63	solute carrier family 22 member 6	Homo sapiens	67-74
31341258-11	2020	These results suggest that LEF/TER increased the kidney accumulation of acyclovir by inhibiting the efflux transporter MRP2, which increased its kidney/plasma ratio and renal injury risk.	Acyclovir	72-81	ATP binding cassette subfamily C member 2	Rattus norvegicus	119-123
31341258-12	2020	However, the inhibitory effects of LEF/TER on OAT1/3 reduced the tubular cells" uptake of acyclovir and increased the plasma concentration.	Acyclovir	90-99	solute carrier family 22 member 6	Rattus norvegicus	46-52
31439560-6	2019	While there is no international consensus on the recommended duration of treatment for zoster with neurological complications, she was treated with intravenous acyclovir for 10 days with good clinical response.	Acyclovir	160-169	Src homology 2 domain containing E	Homo sapiens	127-130
31762503-3	2019	This study evaluated the antiviral effect of sulfated polysaccharide of Adenanthera pavonina (SPAp) against acyclovir (ACV)-resistant (AR-29) and sensitive (KOS) herpes simplex virus strains.	Acyclovir	108-117	surfactant associated protein A1	Mus musculus	94-98
31504577-8	2019	RESULTS: Increased CSF:serum albumin ratio, as well as decreased renal function and high aciclovir doses, was associated with increased aciclovir and CMMG concentrations in the CSF.	Acyclovir	136-145	albumin	Homo sapiens	29-36
32312162-1	2020	ABSTRACTEsters of the antiherpetic drugs ganciclovir, penciclovir with the bile acids (cholic, chenodeoxycholic and deoxycholic) and amino acid esters of acyclovir were generated and evaluated for their in vitro antiviral activity against herpes simplex viruses type 1 and type 2 (HSV-1, HSV-2).	Acyclovir	154-163	type 1 and type 2	None	262-279
31100505-10	2019	One mutation associated with resistance to acyclovir (M183stop) was found inside the UL23 gene in one HSV2 isolate.	Acyclovir	43-52	involved in nucleotide metabolism	Human alphaherpesvirus 2	85-89
31152759-3	2019	The UL23, UL30, and UL5 genes are of greatest interest as these encode, respectively, thymidine kinase, DNA polymerase, and helicase, which, if mutated may affect the effectiveness of acyclovir, foscarnet, cidofovir, and helicase-primase inhibitors.	Acyclovir	184-193	involved in nucleotide metabolism	Human alphaherpesvirus 1	4-8
31152759-3	2019	The UL23, UL30, and UL5 genes are of greatest interest as these encode, respectively, thymidine kinase, DNA polymerase, and helicase, which, if mutated may affect the effectiveness of acyclovir, foscarnet, cidofovir, and helicase-primase inhibitors.	Acyclovir	184-193	DNA polymerase catalytic subunit	Human alphaherpesvirus 1	10-14
31152759-3	2019	The UL23, UL30, and UL5 genes are of greatest interest as these encode, respectively, thymidine kinase, DNA polymerase, and helicase, which, if mutated may affect the effectiveness of acyclovir, foscarnet, cidofovir, and helicase-primase inhibitors.	Acyclovir	184-193	helicase-primase helicase subunit	Human alphaherpesvirus 1	20-23
31152759-3	2019	The UL23, UL30, and UL5 genes are of greatest interest as these encode, respectively, thymidine kinase, DNA polymerase, and helicase, which, if mutated may affect the effectiveness of acyclovir, foscarnet, cidofovir, and helicase-primase inhibitors.	Acyclovir	184-193	involved in nucleotide metabolism	Human alphaherpesvirus 1	86-132
31152759-3	2019	The UL23, UL30, and UL5 genes are of greatest interest as these encode, respectively, thymidine kinase, DNA polymerase, and helicase, which, if mutated may affect the effectiveness of acyclovir, foscarnet, cidofovir, and helicase-primase inhibitors.	Acyclovir	184-193	helicase for meiosis 1	Homo sapiens	124-132
31152759-9	2019	Moreover, the UL23 substitution L242P was added to ACV resistance-related mutations.	Acyclovir	51-54	involved in nucleotide metabolism	Human alphaherpesvirus 1	14-18
30677427-7	2019	The next most potent agents included cidofovir, ganciclovir, foscarnet, and acyclovir with EC50 values between 0.1 muM and >10 muM for cytomegalovirus, herpes simplex virus, and adenovirus.	Acyclovir	76-85	latexin	Homo sapiens	115-118
31089128-3	2019	Here we assess the immunomodulatory potential of PSA in HSE by infecting PSA or PBS treated 129S6 mice with HSV1, followed by delayed Acyclovir (ACV) treatment as often occurs in the clinical setting.	Acyclovir	134-143	aminopeptidase puromycin sensitive	Mus musculus	49-52
30677427-7	2019	The next most potent agents included cidofovir, ganciclovir, foscarnet, and acyclovir with EC50 values between 0.1 muM and >10 muM for cytomegalovirus, herpes simplex virus, and adenovirus.	Acyclovir	76-85	latexin	Homo sapiens	130-133
30682491-4	2019	Acyclovir"s bioaccessibility was studied using the dynamic TNO gastro-Intestinal Model (TIM-1).	Acyclovir	0-9	Rho guanine nucleotide exchange factor 5	Homo sapiens	88-93
30403989-6	2018	The activation of caspase-3 and the presence of nuclear DNA fragmentation confirmed the induction of apoptosis in ACV-treated cells.	Acyclovir	114-117	caspase 3	Homo sapiens	18-27
29111864-1	2017	PURPOSE: The aim of the present study was to develop acyclovir (ACV) ocular drug delivery systems of bovine serum albumin (BSA) nanoparticles as well as to assess their in vitro transcorneal permeation across human corneal epithelial (HCE-T) cell multilayers.	Acyclovir	53-62	albumin	Homo sapiens	108-121
30775686-3	2018	Objective: This study evaluated the potential role of the Vit C and menthone on the DNA damage in rat spermatozoa induced by the ACV.	Acyclovir	129-132	vitrin	Rattus norvegicus	58-61
30144085-5	2018	The ACV and the ACV-MP (66.67 muM) inhibited a cytopathic effect (CPE) induced by the CyHV-3 virus in the CCB (ACV by 66%, ACV-MP by 58%) and the KF1 (ACV by 25%, ACV-MP by 37%).	Acyclovir	4-7	latexin	Homo sapiens	30-33
30144085-5	2018	The ACV and the ACV-MP (66.67 muM) inhibited a cytopathic effect (CPE) induced by the CyHV-3 virus in the CCB (ACV by 66%, ACV-MP by 58%) and the KF1 (ACV by 25%, ACV-MP by 37%).	Acyclovir	16-19	latexin	Homo sapiens	30-33
30144085-5	2018	The ACV and the ACV-MP (66.67 muM) inhibited a cytopathic effect (CPE) induced by the CyHV-3 virus in the CCB (ACV by 66%, ACV-MP by 58%) and the KF1 (ACV by 25%, ACV-MP by 37%).	Acyclovir	16-19	latexin	Homo sapiens	30-33
29427675-10	2018	In conclusion, the significance of single aa changes in HSV-2 TK on ACV/PCV resistance was clarified by the construction and phenotypic testing of recombinant viral strains.	Acyclovir	68-71	involved in nucleotide metabolism	Human alphaherpesvirus 2	62-64
29291454-3	2018	At optimal experimental conditions, oxidation current showed a wide linear response for ACV in the concentration range from 10 nM to 30 muM.	Acyclovir	88-91	latexin	Homo sapiens	136-139
29291454-4	2018	The proposed sensor exhibited pronounced analytical performance for the determination of ACV with limit of detection corresponding to 1.8 nM and high sensitivity of 15.4 muA muM-1.	Acyclovir	89-92	PWWP domain containing 3A, DNA repair factor	Homo sapiens	174-179
30775686-12	2018	Conclusion: The present results showed that Vit C and menthone at higher dose have a good compensatory effect with significant reduction in DNA damages in sperm cells by reversing the adverse effect of ACV on the reproductive system in male rat.	Acyclovir	202-205	vitrin	Rattus norvegicus	44-47
30138624-11	2018	The docking study revealed three separate ligand binding pockets within the hOCT1 translocation pathway, defined by their interactions with three prototypical substrates: MPP+, TEA, and acyclovir.	Acyclovir	186-195	solute carrier family 22 member 1	Homo sapiens	76-81
29755538-5	2018	The calibration graph was linear over the concentration range 0.089 to 7.96 microg mL-1 for ACV determination with a detection limit of 0.067 microg mL-1.	Acyclovir	92-95	L1 cell adhesion molecule	Mus musculus	83-87
29755538-5	2018	The calibration graph was linear over the concentration range 0.089 to 7.96 microg mL-1 for ACV determination with a detection limit of 0.067 microg mL-1.	Acyclovir	92-95	L1 cell adhesion molecule	Mus musculus	149-153
29111864-1	2017	PURPOSE: The aim of the present study was to develop acyclovir (ACV) ocular drug delivery systems of bovine serum albumin (BSA) nanoparticles as well as to assess their in vitro transcorneal permeation across human corneal epithelial (HCE-T) cell multilayers.	Acyclovir	64-67	albumin	Homo sapiens	108-121
29111864-1	2017	PURPOSE: The aim of the present study was to develop acyclovir (ACV) ocular drug delivery systems of bovine serum albumin (BSA) nanoparticles as well as to assess their in vitro transcorneal permeation across human corneal epithelial (HCE-T) cell multilayers.	Acyclovir	64-67	RNA guanylyltransferase and 5'-phosphatase	Homo sapiens	235-238
29111864-7	2017	The in vitro transcorneal permeation results revealed that ACV could permeate through the HCE-T cell multilayers significantly higher from BSA nanoparticles than from aqueous ACV solutions.	Acyclovir	59-62	RNA guanylyltransferase and 5'-phosphatase	Homo sapiens	90-93
29111864-9	2017	ACV could increasingly permeate through the multilayers of HCE-T cells from the ACV-loaded BSA nanoparticles.	Acyclovir	0-3	RNA guanylyltransferase and 5'-phosphatase	Homo sapiens	59-62
29111864-9	2017	ACV could increasingly permeate through the multilayers of HCE-T cells from the ACV-loaded BSA nanoparticles.	Acyclovir	80-83	RNA guanylyltransferase and 5'-phosphatase	Homo sapiens	59-62
28770489-1	2017	PURPOSE: We developed simulation and modeling methods to predict the in vivo pharmacokinetic profiles of acyclovir, following escalating oral doses of valacyclovir, in wildtype and Pept1 knockout mice.	Acyclovir	105-114	solute carrier family 15 (oligopeptide transporter), member 1	Mus musculus	181-186
28956767-9	2017	Taken together, our results demonstrate that the exonuclease activity of UL12 is essential for the production of infectious virus and may be considered a target for development of antiviral agents.IMPORTANCE Herpes simplex virus is a major pathogen, and although nucleoside analogs such as acyclovir are highly effective in controlling HSV-1 or -2 infections in immunocompetent individuals, their use in immunocompromised patients is complicated by the development of resistance.	Acyclovir	290-299	deoxyribonuclease	Human alphaherpesvirus 1	73-77
29113080-0	2017	Biophysical and In Silico Studies of the Interaction between the Anti-Viral Agents Acyclovir and Penciclovir, and Human Serum Albumin.	Acyclovir	83-92	albumin	Homo sapiens	120-133
28637759-5	2017	Inhibition of the JNK pathway blocked viral replication in a manner distinct from that of acyclovir, and an acyclovir-resistant VZV isolate was as sensitive to the effects of JNK inhibition as an acyclovir-sensitive VZV isolate in neurons.	Acyclovir	108-117	mitogen-activated protein kinase 8	Homo sapiens	175-178
28705621-0	2017	Functionalized PLA-PEG nanoparticles targeting intestinal transporter PepT1 for oral delivery of acyclovir.	Acyclovir	97-106	solute carrier family 15 member 1	Homo sapiens	70-75
28705621-1	2017	Targeting intestinal di- and tri-peptide transporter PepT1 with prodrugs is a successful strategy to improve oral drug bioavailability, as demonstrated with valacyclovir, a prodrug of acyclovir.	Acyclovir	160-169	solute carrier family 15 member 1	Homo sapiens	53-58
28705621-9	2017	Acyclovir encapsulation did not statistically modify AUC or Cmax, but increased t1/2 and MRT 1.3-fold as compared to free acyclovir.	Acyclovir	0-9	sorting nexin 27	Homo sapiens	89-94
28982161-10	2017	The TAF2 and ACV release rates and resulting vaginal tissue drug concentrations (medians: TFV, 2.4 ng mg-1; ACV, 0.2 ng mg-1) may be sufficient to protect against HIV and HSV infection, respectively.	Acyclovir	108-111	TATA-box binding protein associated factor 2	Homo sapiens	4-8
28637759-5	2017	Inhibition of the JNK pathway blocked viral replication in a manner distinct from that of acyclovir, and an acyclovir-resistant VZV isolate was as sensitive to the effects of JNK inhibition as an acyclovir-sensitive VZV isolate in neurons.	Acyclovir	108-117	mitogen-activated protein kinase 8	Homo sapiens	175-178
26836009-1	2016	We examined the impact of two clinically approved anti-herpes drugs, acyclovir and Forscarnet (phosphonoformate), on the exonuclease activity of the herpes simplex virus-1 DNA polymerase, UL30.	Acyclovir	69-78	DNA polymerase catalytic subunit	Human alphaherpesvirus 1	188-192
28344640-7	2017	Acyclovir treatment decreases the growth and the proliferation rate of cells and correlates with the upregulated levels of apoptosis associated cytokine Caspase-3.	Acyclovir	0-9	caspase 3	Homo sapiens	153-162
28344640-8	2017	Moreover, acyclovir inhibits colony formation ability and cell invasion capacity of the cancer cells while enhancing the expression of E-cadherin protein in MCF7 cells.	Acyclovir	10-19	cadherin 1	Homo sapiens	135-145
28092836-0	2017	Antiviral drug acyclovir exhibits antitumor activity via targeting betaTrCP1: Molecular docking and dynamics simulation study.	Acyclovir	15-24	beta-transducin repeat containing E3 ubiquitin protein ligase	Homo sapiens	67-76
27497730-9	2016	In the ACV-treated rats, increased levels of protein (PRO), occult blood (BLD), white blood cell (WBC), and NAG activity in urine were observed, while the urine creatinine and urea nitrogen levels showed a decrease compared with the control.	Acyclovir	7-10	N-acetyl-alpha-glucosaminidase	Homo sapiens	108-111
27668908-10	2016	A 21-day course of acyclovir therapy was administered with consistent improvement of clinical findings and disappearance of HSV-2-DNA within CSF.	Acyclovir	19-28	colony stimulating factor 2	Homo sapiens	141-144
27487292-10	2017	Different from (PhSe)2 , acyclovir (positive control), caused an increase in ADA activity and a decrease in hepatic CAT activity.	Acyclovir	25-34	adenosine deaminase	Homo sapiens	77-80
27487292-10	2017	Different from (PhSe)2 , acyclovir (positive control), caused an increase in ADA activity and a decrease in hepatic CAT activity.	Acyclovir	25-34	catalase	Homo sapiens	116-119
27424493-6	2016	IPAD completely suppressed ICP8 transcription and translation as well as DNA replication and gD expression in the three strains tested, while acyclovir suppressed transcription and translation of UL30 and gD of HSV-2, HSV-1, but had no effect on DR-HSV-1.	Acyclovir	142-151	involved in DNA replication	Human alphaherpesvirus 2	196-200
26816936-3	2015	The authors present a case of HSVE with normal CSF analysis, but typical MRI findings consistent with HSE and CSF PCR positive for Herpes simplex virus1 DNA, who responded to Acyclovir therapy with complete recovery.	Acyclovir	175-184	colony stimulating factor 2	Homo sapiens	110-113
26669609-10	2016	Also, animals treated with siRNA plus acyclovir demonstrated reduced signs of HSE and mortality, as well as HSV-1 replication inhibition in the brain (83.2%) and TG (74.5%).	Acyclovir	38-47	hydroxysteroid 17-beta dehydrogenase 6	Homo sapiens	78-81
26024233-0	2015	Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity.	Acyclovir	0-9	major histocompatibility complex, class I, B	Homo sapiens	46-51
26024233-6	2015	In agreement with the binding studies, HLA-B*57:01 peptide-elution studies performed in the presence of acyclovir revealed an increased number of endogenously bound peptides with a C-terminal isoleucine.	Acyclovir	104-113	major histocompatibility complex, class I, B	Homo sapiens	39-44
25440915-0	2014	Aciclovir-induced neurotoxicity: Utility of CSF and serum CMMG levels in diagnosis.	Acyclovir	0-9	colony stimulating factor 2	Homo sapiens	44-47
25923913-0	2015	Acyclovir Therapy Reduces the CD4+ T Cell Response against the Immunodominant pp65 Protein from Cytomegalovirus in Immune Competent Individuals.	Acyclovir	0-9	CD4 molecule	Homo sapiens	30-33
25440915-3	2014	This case illustrates how aciclovir induced neurotoxicity can present and how it can be diagnosed using quantitative assays of aciclovir and its metabolite in the CSF and serum.	Acyclovir	127-136	colony stimulating factor 2	Homo sapiens	163-166
25175747-5	2014	Specific uptake of cimetidine, acyclovir, metformin, and terbutaline was observed in human embryonic kidney 293 cells transfected with murine Oct1 or Oct2.	Acyclovir	31-40	POU domain, class 2, transcription factor 2	Mus musculus	150-154
25175747-6	2014	The milk-to-plasma concentration ratio (M/P) values of cimetidine and acyclovir were significantly decreased in Bcrp knockout and Oct1/2 double-knockout (DKO) mice compared with control FVB mice, whereas the M/P values of terbutaline and metformin were significantly decreased in Oct1/2 DKO mice alone.	Acyclovir	70-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	112-116
25175747-5	2014	Specific uptake of cimetidine, acyclovir, metformin, and terbutaline was observed in human embryonic kidney 293 cells transfected with murine Oct1 or Oct2.	Acyclovir	31-40	solute carrier family 22 (organic cation transporter), member 1	Mus musculus	142-146
25175747-6	2014	The milk-to-plasma concentration ratio (M/P) values of cimetidine and acyclovir were significantly decreased in Bcrp knockout and Oct1/2 double-knockout (DKO) mice compared with control FVB mice, whereas the M/P values of terbutaline and metformin were significantly decreased in Oct1/2 DKO mice alone.	Acyclovir	70-79	solute carrier family 22 (organic cation transporter), member 1	Mus musculus	130-136
25175747-6	2014	The milk-to-plasma concentration ratio (M/P) values of cimetidine and acyclovir were significantly decreased in Bcrp knockout and Oct1/2 double-knockout (DKO) mice compared with control FVB mice, whereas the M/P values of terbutaline and metformin were significantly decreased in Oct1/2 DKO mice alone.	Acyclovir	70-79	solute carrier family 22 (organic cation transporter), member 1	Mus musculus	130-134
24682316-9	2014	Nonetheless, lower levels of IL-12 p40 and IL-27 p28 proteins were found in the supernatants of macrophages treated with either GSH-C4 or ACV, likely as an indirect consequence of inhibited HSV-1 replication.	Acyclovir	138-141	interleukin 9	Homo sapiens	35-38
24682316-9	2014	Nonetheless, lower levels of IL-12 p40 and IL-27 p28 proteins were found in the supernatants of macrophages treated with either GSH-C4 or ACV, likely as an indirect consequence of inhibited HSV-1 replication.	Acyclovir	138-141	interleukin 27	Homo sapiens	43-48
24682316-9	2014	Nonetheless, lower levels of IL-12 p40 and IL-27 p28 proteins were found in the supernatants of macrophages treated with either GSH-C4 or ACV, likely as an indirect consequence of inhibited HSV-1 replication.	Acyclovir	138-141	golgi SNAP receptor complex member 1	Homo sapiens	49-52
25055032-8	2014	Among these, six proteins (MHC class II antigen, glyoxalase 1, peroxiredoxin 1, alphaB-crystallin, fibroblast growth factor receptor 1-IIIb, and cytochrome c oxidase subunit Vb) were identified in association with ACV-induced nephrotoxicity.	Acyclovir	214-217	cytochrome c oxidase subunit 5B	Mus musculus	145-176
25055032-10	2014	The differential expression levels of alpha-BC, Prx1, Glo I and CcO Vb suggest that oxidative damage and mitochondrial injury may be involved in ACV-induced nephrotoxicity.	Acyclovir	145-148	peroxiredoxin 1	Mus musculus	48-52
24915059-1	2014	The five tautomers of the drug acyclovir (ACV) were determined and optimised at the MP2 and B3LYP quantum chemical levels of theory.	Acyclovir	31-40	tryptase pseudogene 1	Homo sapiens	84-87
24915059-1	2014	The five tautomers of the drug acyclovir (ACV) were determined and optimised at the MP2 and B3LYP quantum chemical levels of theory.	Acyclovir	42-45	tryptase pseudogene 1	Homo sapiens	84-87
24794394-8	2014	Interference of capsid proteins VP23 (UL18) and VP5 (UL19) individually or jointly greatly affected the replication of clinically isolated acyclovir-resistant HSV-1 as well as HSV-1/F and HSV-2/333.	Acyclovir	139-148	capsid triplex subunit 2	Human alphaherpesvirus 1	38-42
24794394-8	2014	Interference of capsid proteins VP23 (UL18) and VP5 (UL19) individually or jointly greatly affected the replication of clinically isolated acyclovir-resistant HSV-1 as well as HSV-1/F and HSV-2/333.	Acyclovir	139-148	major capsid protein	Human alphaherpesvirus 1	53-57
24374341-2	2014	This compound competitively inhibited HSV-TK catalyzed phosphorylation of acyclovir with Ki=250 muM (95% CI: 106-405 muM) and dose-dependently increased the rate of the ATP hydrolysis with KM=112 muM (95% CI: 28-195 muM).	Acyclovir	74-83	latexin	Homo sapiens	96-99
24395733-5	2014	The negatively charged E-PC/E-PG liposomes could encapsulate more ACV than neutral E-PC liposomes.	Acyclovir	66-69	epithelial mitogen	Homo sapiens	28-32
24374341-2	2014	This compound competitively inhibited HSV-TK catalyzed phosphorylation of acyclovir with Ki=250 muM (95% CI: 106-405 muM) and dose-dependently increased the rate of the ATP hydrolysis with KM=112 muM (95% CI: 28-195 muM).	Acyclovir	74-83	latexin	Homo sapiens	117-120
24374341-2	2014	This compound competitively inhibited HSV-TK catalyzed phosphorylation of acyclovir with Ki=250 muM (95% CI: 106-405 muM) and dose-dependently increased the rate of the ATP hydrolysis with KM=112 muM (95% CI: 28-195 muM).	Acyclovir	74-83	latexin	Homo sapiens	117-120
24374341-2	2014	This compound competitively inhibited HSV-TK catalyzed phosphorylation of acyclovir with Ki=250 muM (95% CI: 106-405 muM) and dose-dependently increased the rate of the ATP hydrolysis with KM=112 muM (95% CI: 28-195 muM).	Acyclovir	74-83	latexin	Homo sapiens	117-120
24257111-0	2014	Acyclovir-resistant herpes simplex encephalitis in a patient treated with anti-tumor necrosis factor-alpha monoclonal antibodies.	Acyclovir	0-9	tumor necrosis factor	Homo sapiens	79-106
23337623-8	2013	Additionally, serum amyloid A (SAA) levels were lower in acyclovir than that in control patients (98+-37 vs. 505+-204 microg/mL, P=0.02).	Acyclovir	57-66	serum amyloid A1 cluster	Homo sapiens	14-29
25672698-2	2014	Thanks to the introduction of ACV, the morbidity and mortality of HSE patients have significantly improved.	Acyclovir	30-33	hydroxysteroid 17-beta dehydrogenase 6	Homo sapiens	66-69
25672698-5	2014	The cases of the ACV treatment-resistant HSE patients have been reported.	Acyclovir	17-20	hydroxysteroid 17-beta dehydrogenase 6	Homo sapiens	41-44
24030886-3	2013	It has absorption problems mainly due to its poor solubility in water (about 0.2 g/100 mL at 25 C) and its oral bioavailability is approximately 15%-20% with a half-life of about 3 h. To improve acyclovir solubility and/or its dissolution properties, two cocrystals of this drug were successfully produced with glutaric acid (AGA1:1) and fumaric acid (AFA1:1) as conformers, using a cogrinding method.	Acyclovir	195-204	AFA1	Homo sapiens	352-356
24030886-8	2013	AFA1:1 showed the most rapid dissolution behavior in water; within 10 min, the drug was released completely, while just 60% of acyclovir was dissolved in 1 h.	Acyclovir	127-136	AFA1	Homo sapiens	0-4
23867133-3	2013	The formation of P-tau, but not of Abeta, depends on viral DNA replication, but nonetheless, three antiviral agents that inhibit HSV1 DNA replication, including acyclovir (ACV), were found to reduce greatly the level of Abeta as well as P-tau, the former probably through prevention of viral spread.	Acyclovir	161-170	microtubule associated protein tau	Homo sapiens	19-22
23867133-3	2013	The formation of P-tau, but not of Abeta, depends on viral DNA replication, but nonetheless, three antiviral agents that inhibit HSV1 DNA replication, including acyclovir (ACV), were found to reduce greatly the level of Abeta as well as P-tau, the former probably through prevention of viral spread.	Acyclovir	172-175	microtubule associated protein tau	Homo sapiens	19-22
23867133-6	2013	We found that BAY 57-1293 is more efficient than ACV not only in inhibiting HSV1 replication, confirming previous studies, but also in decreasing Abeta and P-tau formation.	Acyclovir	49-52	microtubule associated protein tau	Homo sapiens	158-161
23657675-1	2013	PURPOSE: Biotinylated lipid prodrugs of acyclovir (ACV) were designed to target the sodium dependent multivitamin transporter (SMVT) on the cornea to facilitate enhanced cellular absorption of ACV.	Acyclovir	40-49	solute carrier family 5 member 6	Homo sapiens	84-125
23657675-1	2013	PURPOSE: Biotinylated lipid prodrugs of acyclovir (ACV) were designed to target the sodium dependent multivitamin transporter (SMVT) on the cornea to facilitate enhanced cellular absorption of ACV.	Acyclovir	40-49	solute carrier family 5 member 6	Homo sapiens	127-131
23657675-1	2013	PURPOSE: Biotinylated lipid prodrugs of acyclovir (ACV) were designed to target the sodium dependent multivitamin transporter (SMVT) on the cornea to facilitate enhanced cellular absorption of ACV.	Acyclovir	51-54	solute carrier family 5 member 6	Homo sapiens	84-125
23657675-1	2013	PURPOSE: Biotinylated lipid prodrugs of acyclovir (ACV) were designed to target the sodium dependent multivitamin transporter (SMVT) on the cornea to facilitate enhanced cellular absorption of ACV.	Acyclovir	51-54	solute carrier family 5 member 6	Homo sapiens	127-131
23657675-1	2013	PURPOSE: Biotinylated lipid prodrugs of acyclovir (ACV) were designed to target the sodium dependent multivitamin transporter (SMVT) on the cornea to facilitate enhanced cellular absorption of ACV.	Acyclovir	193-196	solute carrier family 5 member 6	Homo sapiens	84-125
23657675-1	2013	PURPOSE: Biotinylated lipid prodrugs of acyclovir (ACV) were designed to target the sodium dependent multivitamin transporter (SMVT) on the cornea to facilitate enhanced cellular absorption of ACV.	Acyclovir	193-196	solute carrier family 5 member 6	Homo sapiens	127-131
23117047-5	2013	The acyclovir loading was observed to be highest in dendrimer drug conjugate (DAc) compared to other DCys1Ac and DCys2Ac conjugates.	Acyclovir	4-13	arylacetamide deacetylase	Homo sapiens	78-81
23264448-1	2013	The purpose of this study was to quantitatively determine the contribution of PepT1 [peptide transporter 1 (SLC15A1)] to the intestinal permeability of valacyclovir, an ester prodrug of the antiviral drug acyclovir.	Acyclovir	155-164	solute carrier family 15 (oligopeptide transporter), member 1	Mus musculus	78-83
23264448-1	2013	The purpose of this study was to quantitatively determine the contribution of PepT1 [peptide transporter 1 (SLC15A1)] to the intestinal permeability of valacyclovir, an ester prodrug of the antiviral drug acyclovir.	Acyclovir	155-164	solute carrier family 15 (oligopeptide transporter), member 1	Mus musculus	85-106
23264448-1	2013	The purpose of this study was to quantitatively determine the contribution of PepT1 [peptide transporter 1 (SLC15A1)] to the intestinal permeability of valacyclovir, an ester prodrug of the antiviral drug acyclovir.	Acyclovir	155-164	solute carrier family 15 (oligopeptide transporter), member 1	Mus musculus	108-115
23196129-5	2013	Because many antiviral medications are Oat substrates, including those crucial in the treatment of HIV infections, the interaction of the antivirals zidovudine, acyclovir, tenofovir, lamivudine, and stavudine, with Oat1 and Oat3 in CP, was investigated by determining the inhibition of 6CF uptake.	Acyclovir	161-170	solute carrier family 22 (organic anion transporter), member 6	Mus musculus	215-219
23924683-2	2013	A secondary aim was to characterize the role of PepT1 on the tissue distribution of its active metabolite, acyclovir.	Acyclovir	107-116	solute carrier family 15 (oligopeptide transporter), member 1	Mus musculus	48-53
23507869-7	2013	Miltefosine (50 muM), a licensed drug that blocks Akt phosphorylation, inhibited HSV-induced calcium release, viral entry, and plaque formation following infection with acyclovir-sensitive and resistant clinical isolates.	Acyclovir	169-178	latexin	Homo sapiens	16-19
23279938-3	2013	In this work, new carboxylated cyclodextrin-based nanosponges (Carb-NS) carrying carboxylic groups within their structure were purposely designed as novel Acyclovir carriers.	Acyclovir	155-164	syntaxin 8	Homo sapiens	63-67
23279938-5	2013	The behaviour of Carb-NS, with respect to the incorporation and delivery of Acyclovir, was compared to that of NS, previously investigated as a drug carrier.	Acyclovir	76-85	syntaxin 8	Homo sapiens	17-21
23279938-8	2013	The Acyclovir loading into Carb-NS was higher than that obtained using NS, reaching about 70% (w/w).	Acyclovir	4-13	syntaxin 8	Homo sapiens	27-31
23279938-9	2013	In vitro release studies showed the release kinetics of Acyclovir from Carb-NS to be prolonged in comparison with those observed with NS, with no initial burst effect.	Acyclovir	56-65	syntaxin 8	Homo sapiens	71-75
23279938-11	2013	Enhanced antiviral activity against a clinical isolate of HSV-1 was obtained using Acyclovir loaded in Carb-NS.	Acyclovir	83-92	syntaxin 8	Homo sapiens	103-107
23268600-5	2013	Our analysis identified SLC22A7 (OAT2), a carrier for the antiviral drug acyclovir, in the corneal epithelium, in addition to ABCG2 (BCRP), an important xenobiotic efflux pump, in retinal nerve fibers and the retinal pigment epithelium.	Acyclovir	73-82	solute carrier family 22 member 7	Homo sapiens	24-31
23268600-5	2013	Our analysis identified SLC22A7 (OAT2), a carrier for the antiviral drug acyclovir, in the corneal epithelium, in addition to ABCG2 (BCRP), an important xenobiotic efflux pump, in retinal nerve fibers and the retinal pigment epithelium.	Acyclovir	73-82	solute carrier family 22 member 7	Homo sapiens	33-37
23337623-8	2013	Additionally, serum amyloid A (SAA) levels were lower in acyclovir than that in control patients (98+-37 vs. 505+-204 microg/mL, P=0.02).	Acyclovir	57-66	serum amyloid A1 cluster	Homo sapiens	31-34
23435814-6	2013	Moreover, acyclovir therapy was effective in 81% of patients who showed high specific IgA titers.	Acyclovir	10-19	immunoglobulin heavy variable 4-38-2-like	Homo sapiens	86-89
24185376-0	2013	Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme.	Acyclovir	32-41	dipeptidyl peptidase 4	Homo sapiens	59-82
24185376-0	2013	Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme.	Acyclovir	32-41	dipeptidyl peptidase 4	Homo sapiens	91-95
24185376-1	2013	We herein report for the first time the successful use of the dipeptidyl peptidase IV (DPPIV/CD26) prodrug approach to guanine derivatives such as the antiviral acyclovir (ACV).	Acyclovir	161-170	dipeptidyl peptidase 4	Homo sapiens	62-85
24185376-1	2013	We herein report for the first time the successful use of the dipeptidyl peptidase IV (DPPIV/CD26) prodrug approach to guanine derivatives such as the antiviral acyclovir (ACV).	Acyclovir	161-170	dipeptidyl peptidase 4	Homo sapiens	87-92
24185376-1	2013	We herein report for the first time the successful use of the dipeptidyl peptidase IV (DPPIV/CD26) prodrug approach to guanine derivatives such as the antiviral acyclovir (ACV).	Acyclovir	161-170	dipeptidyl peptidase 4	Homo sapiens	93-97
24185376-1	2013	We herein report for the first time the successful use of the dipeptidyl peptidase IV (DPPIV/CD26) prodrug approach to guanine derivatives such as the antiviral acyclovir (ACV).	Acyclovir	172-175	dipeptidyl peptidase 4	Homo sapiens	62-85
24185376-1	2013	We herein report for the first time the successful use of the dipeptidyl peptidase IV (DPPIV/CD26) prodrug approach to guanine derivatives such as the antiviral acyclovir (ACV).	Acyclovir	172-175	dipeptidyl peptidase 4	Homo sapiens	87-92
24185376-1	2013	We herein report for the first time the successful use of the dipeptidyl peptidase IV (DPPIV/CD26) prodrug approach to guanine derivatives such as the antiviral acyclovir (ACV).	Acyclovir	172-175	dipeptidyl peptidase 4	Homo sapiens	93-97
24185376-5	2013	Both prodrugs converted to VACV (for 4) or ACV (for 3) upon exposure to purified DPPIV/CD26 or human or bovine serum.	Acyclovir	28-31	dipeptidyl peptidase 4	Homo sapiens	81-86
24185376-5	2013	Both prodrugs converted to VACV (for 4) or ACV (for 3) upon exposure to purified DPPIV/CD26 or human or bovine serum.	Acyclovir	28-31	dipeptidyl peptidase 4	Homo sapiens	87-91
22906425-1	2012	The analysis of the viral thymidine kinase (TK) genotype is of rising significance for testing resistance of herpes simplex virus (HSV) to antivirals especially acyclovir.	Acyclovir	161-170	involved in nucleotide metabolism	Human alphaherpesvirus 1	26-42
23744435-0	2013	Benzylpenicillin inhibits the renal excretion of acyclovir by OAT1 and OAT3.	Acyclovir	49-58	solute carrier family 22 member 6	Homo sapiens	62-66
23744435-0	2013	Benzylpenicillin inhibits the renal excretion of acyclovir by OAT1 and OAT3.	Acyclovir	49-58	solute carrier family 22 member 8	Homo sapiens	71-75
23744435-7	2013	CONCLUSIONS: It indicates that acyclovir is a substrate for OAT1 and OAT3.	Acyclovir	31-40	solute carrier family 22 member 6	Homo sapiens	60-64
23744435-7	2013	CONCLUSIONS: It indicates that acyclovir is a substrate for OAT1 and OAT3.	Acyclovir	31-40	solute carrier family 22 member 8	Homo sapiens	69-73
23744435-8	2013	PCG inhibits the renal excretion of acyclovir by inhibiting renal transporters OAT1 and OAT3 in vivo and in vitro.	Acyclovir	36-45	solute carrier family 22 member 6	Homo sapiens	79-83
23744435-8	2013	PCG inhibits the renal excretion of acyclovir by inhibiting renal transporters OAT1 and OAT3 in vivo and in vitro.	Acyclovir	36-45	solute carrier family 22 member 8	Homo sapiens	88-92
22728397-4	2012	JBP485 (a substrate for OAT1 and OAT3), p-aminohippurate (PAH) (a substrate for OAT1) and benzylpenicillin (PCG) (a substrate for OAT3) could decrease the uptake of acyclovir in kidney slices and in hOAT1-/hOAT3-HEK293 cells.	Acyclovir	165-174	solute carrier family 22 member 6	Homo sapiens	24-28
22728397-0	2012	Inhibitory effect of JBP485 on renal excretion of acyclovir by the inhibition of OAT1 and OAT3.	Acyclovir	50-59	solute carrier family 22 member 6	Homo sapiens	81-85
22728397-4	2012	JBP485 (a substrate for OAT1 and OAT3), p-aminohippurate (PAH) (a substrate for OAT1) and benzylpenicillin (PCG) (a substrate for OAT3) could decrease the uptake of acyclovir in kidney slices and in hOAT1-/hOAT3-HEK293 cells.	Acyclovir	165-174	solute carrier family 22 member 6	Homo sapiens	80-84
22728397-0	2012	Inhibitory effect of JBP485 on renal excretion of acyclovir by the inhibition of OAT1 and OAT3.	Acyclovir	50-59	solute carrier family 22 member 8	Homo sapiens	90-94
22728397-4	2012	JBP485 (a substrate for OAT1 and OAT3), p-aminohippurate (PAH) (a substrate for OAT1) and benzylpenicillin (PCG) (a substrate for OAT3) could decrease the uptake of acyclovir in kidney slices and in hOAT1-/hOAT3-HEK293 cells.	Acyclovir	165-174	solute carrier family 22 member 8	Homo sapiens	130-134
22728397-1	2012	The purpose is to investigate whether the targets of drug-drug interactions (DDIs) between JBP485 and acyclovir are OAT1 and OAT3 in kidney.	Acyclovir	102-111	solute carrier family 22 member 6	Homo sapiens	116-120
22728397-4	2012	JBP485 (a substrate for OAT1 and OAT3), p-aminohippurate (PAH) (a substrate for OAT1) and benzylpenicillin (PCG) (a substrate for OAT3) could decrease the uptake of acyclovir in kidney slices and in hOAT1-/hOAT3-HEK293 cells.	Acyclovir	165-174	solute carrier family 22 member 6	Homo sapiens	199-204
22728397-1	2012	The purpose is to investigate whether the targets of drug-drug interactions (DDIs) between JBP485 and acyclovir are OAT1 and OAT3 in kidney.	Acyclovir	102-111	solute carrier family 22 member 8	Homo sapiens	125-129
22728397-4	2012	JBP485 (a substrate for OAT1 and OAT3), p-aminohippurate (PAH) (a substrate for OAT1) and benzylpenicillin (PCG) (a substrate for OAT3) could decrease the uptake of acyclovir in kidney slices and in hOAT1-/hOAT3-HEK293 cells.	Acyclovir	165-174	solute carrier family 22 member 8	Homo sapiens	206-211
22728397-5	2012	These results suggest that JBP485 inhibits the renal excretion of acyclovir by inhibiting renal transporters OAT1 and OAT3 in vivo and in vitro.	Acyclovir	66-75	solute carrier family 22 member 6	Homo sapiens	109-113
22728397-5	2012	These results suggest that JBP485 inhibits the renal excretion of acyclovir by inhibiting renal transporters OAT1 and OAT3 in vivo and in vitro.	Acyclovir	66-75	solute carrier family 22 member 8	Homo sapiens	118-122
21859328-0	2011	Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity.	Acyclovir	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	39-71
22692074-15	2012	Overall, results from these studies clearly suggest that these biotinylated lipid prodrugs of ACV possess enhanced affinity towards SMVT.	Acyclovir	94-97	solute carrier family 5 member 6	Canis lupus familiaris	132-136
22704890-3	2012	The synthetic analogues SNX-25a, SNX-2112 and SNX-7081, which selectively bind to the N-terminal ATP pocket of heat shock protein 90 (HSP90), exhibited significant anti-HSV-1 and HSV-2 activities at non-cytotoxic concentrations in Vero cells, with EC(50) values close to that of acyclovir (ACV).	Acyclovir	279-288	heat shock protein 90 alpha family class A member 1	Homo sapiens	134-139
22704890-3	2012	The synthetic analogues SNX-25a, SNX-2112 and SNX-7081, which selectively bind to the N-terminal ATP pocket of heat shock protein 90 (HSP90), exhibited significant anti-HSV-1 and HSV-2 activities at non-cytotoxic concentrations in Vero cells, with EC(50) values close to that of acyclovir (ACV).	Acyclovir	290-293	heat shock protein 90 alpha family class A member 1	Homo sapiens	134-139
22704890-4	2012	The in vivo antiviral potentials were then confirmed using a herpes simplex keratitis (HSK) rabbit model, where eye gels containing 0.1% or 0.025% SNX-25a displayed the highest efficacies against HSV-1 infection, which were better than that obtained with 0.1% ACV.	Acyclovir	260-263	sorting nexin-25	Oryctolagus cuniculus	147-153
22515095-8	2012	The FRET efficient was remarkably decreased and then disappeared during cellular apoptosis, which indicated that the TK-GFP expressing ACC-M cells apoptosis, induced by ACV, was via a caspase3-dependent pathway.	Acyclovir	169-172	caspase 3	Homo sapiens	184-192
22662200-5	2012	An acyclic guanosine prodrug analog, valaciclovir, was shown to stabilize GDA to the same degree as the natural substrate, guanine, with a DeltaT(agg) around 7 C. Aciclovir, penciclovir, ganciclovir, thioguanine and mercaptopurine were also identified as ligands for GDA.	Acyclovir	163-172	guanine deaminase	Homo sapiens	74-77
22005269-3	2011	We postulated that acyclovir is metabolized by the alcohol dehydrogenase (ADH) enzyme to acyclovir aldehyde, which is metabolized by the aldehyde dehydrognase 2 (ALDH2) enzyme to 9-carboxymethoxymethylguanine (CMMG).	Acyclovir	19-28	alcohol dehydrogenase 1A (class I), alpha polypeptide	Homo sapiens	74-77
22005269-3	2011	We postulated that acyclovir is metabolized by the alcohol dehydrogenase (ADH) enzyme to acyclovir aldehyde, which is metabolized by the aldehyde dehydrognase 2 (ALDH2) enzyme to 9-carboxymethoxymethylguanine (CMMG).	Acyclovir	19-28	aldehyde dehydrogenase 2 family member	Homo sapiens	162-167
22190696-6	2012	A previous observation that OAT2 transports cGMP led us to examine whether acyclovir, ganciclovir, and penciclovir are OAT2 substrates; they are guanine-containing antivirals that undergo active tubular secretion.	Acyclovir	75-84	solute carrier family 22 member 7	Homo sapiens	119-123
21859328-0	2011	Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity.	Acyclovir	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	73-77
21859328-0	2011	Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity.	Acyclovir	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	78-83
21859328-0	2011	Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity.	Acyclovir	131-140	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	39-71
21859328-0	2011	Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity.	Acyclovir	131-140	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	73-77
21859328-0	2011	Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity.	Acyclovir	131-140	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	78-83
21859328-2	2011	In mice, Bcrp1 (murine BCRP ortholog) mediates the transport of acyclovir into breast milk.	Acyclovir	64-73	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	9-14
21859328-2	2011	In mice, Bcrp1 (murine BCRP ortholog) mediates the transport of acyclovir into breast milk.	Acyclovir	64-73	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	23-27
21859328-3	2011	It is plausible that acyclovir is also a substrate for the human BCRP.	Acyclovir	21-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	65-69
21859328-4	2011	The objective of the study was to determine whether acyclovir is a substrate for human BCRP.	Acyclovir	52-61	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	87-91
21859328-8	2011	The results suggest that acyclovir is a substrate for human BCRP.	Acyclovir	25-34	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	60-64
21859328-9	2011	The study is the first to provide direct evidence for the role of human BCRP in acyclovir transport and its potential significance with respect to renal tubular transport of acyclovir and the direct renal tubular insult induced by the drug.	Acyclovir	80-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	72-76
21859328-9	2011	The study is the first to provide direct evidence for the role of human BCRP in acyclovir transport and its potential significance with respect to renal tubular transport of acyclovir and the direct renal tubular insult induced by the drug.	Acyclovir	174-183	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	72-76
21566148-9	2011	These DNA complexes utilize a primer-template pair enzymatically chain-terminated by incorporation of acyclo-GMP, the phosphorylated form of the anti-herpes drug acyclovir.	Acyclovir	162-171	5'-nucleotidase, cytosolic II	Homo sapiens	109-112
21539861-2	2011	In this study, the natural polymorphism of the thymidine kinase (TK) and DNA polymerase (pol) genes was examined in 51 clinical VZV isolates sensitive to acyclovir (ACV).	Acyclovir	154-163	thymidine kinase	Human alphaherpesvirus 3	47-63
22096991-1	2011	A thymidine kinase UL23 gene (EC 2.7.1.145) from an acyclovir-sensitive strain L2 of herpes simplex virus type 1 was cloned and expressed in E. coli.	Acyclovir	52-61	involved in nucleotide metabolism	Human alphaherpesvirus 1	19-23
21539861-2	2011	In this study, the natural polymorphism of the thymidine kinase (TK) and DNA polymerase (pol) genes was examined in 51 clinical VZV isolates sensitive to acyclovir (ACV).	Acyclovir	154-163	thymidine kinase	Human alphaherpesvirus 3	65-67
21539861-2	2011	In this study, the natural polymorphism of the thymidine kinase (TK) and DNA polymerase (pol) genes was examined in 51 clinical VZV isolates sensitive to acyclovir (ACV).	Acyclovir	165-168	thymidine kinase	Human alphaherpesvirus 3	47-63
21539861-2	2011	In this study, the natural polymorphism of the thymidine kinase (TK) and DNA polymerase (pol) genes was examined in 51 clinical VZV isolates sensitive to acyclovir (ACV).	Acyclovir	165-168	thymidine kinase	Human alphaherpesvirus 3	65-67
22155911-5	2011	Acyclovir resistance was assigned to frameshift and single non-synonymous mutations of the thymidine kinase (TK) gene in 32 out of 37 HSV-1 strains and in 4 out of 6 HSV-2 strains.	Acyclovir	0-9	involved in nucleotide metabolism	Human alphaherpesvirus 1	91-107
20861476-12	2011	The FIC value for TFT and GCV combined against the acyclovir-resistant HSV-1 strain was 0.84, indicating nonantagonism.	Acyclovir	51-60	C-C motif chemokine ligand 7	Homo sapiens	4-7
22155911-5	2011	Acyclovir resistance was assigned to frameshift and single non-synonymous mutations of the thymidine kinase (TK) gene in 32 out of 37 HSV-1 strains and in 4 out of 6 HSV-2 strains.	Acyclovir	0-9	involved in nucleotide metabolism	Human alphaherpesvirus 1	109-111
22003387-7	2011	Importantly, the anti-HSV1 antiviral agents acyclovir, penciclovir and foscarnet reduced Abeta and P-tau accumulation, as well as HSV1, with foscarnet being less effective in each case.	Acyclovir	44-53	amyloid beta precursor protein	Homo sapiens	89-94
22024514-3	2011	METHODS: In this study, the natural polymorphism of TK and DNA pol genes was examined by DNA sequencing in 56 HSV-1 and 12 HSV-2 strains sensitive to acyclovir.	Acyclovir	150-159	involved in nucleotide metabolism	Human alphaherpesvirus 1	52-54
21519125-5	2011	Furthermore, it was found that the ACV-sensitive (ACV(s)) isolate recovered from the skin lesions that appeared between the episodes of ACV(r) infection at the ages of 8 and 9 contained ACV(r) HSV-1 with the same mutation in the TK gene.	Acyclovir	35-38	involved in nucleotide metabolism	Human alphaherpesvirus 1	229-231
21519125-5	2011	Furthermore, it was found that the ACV-sensitive (ACV(s)) isolate recovered from the skin lesions that appeared between the episodes of ACV(r) infection at the ages of 8 and 9 contained ACV(r) HSV-1 with the same mutation in the TK gene.	Acyclovir	50-53	involved in nucleotide metabolism	Human alphaherpesvirus 1	229-231
21519125-5	2011	Furthermore, it was found that the ACV-sensitive (ACV(s)) isolate recovered from the skin lesions that appeared between the episodes of ACV(r) infection at the ages of 8 and 9 contained ACV(r) HSV-1 with the same mutation in the TK gene.	Acyclovir	50-53	involved in nucleotide metabolism	Human alphaherpesvirus 1	229-231
22003387-7	2011	Importantly, the anti-HSV1 antiviral agents acyclovir, penciclovir and foscarnet reduced Abeta and P-tau accumulation, as well as HSV1, with foscarnet being less effective in each case.	Acyclovir	44-53	microtubule associated protein tau	Homo sapiens	101-104
20568406-7	2010	The aim of this paper was to emphasize the necessity of immediate antiviral therapy with Acyclovir in all cases suspected of HSE.	Acyclovir	89-98	hydroxysteroid 17-beta dehydrogenase 6	Homo sapiens	125-128
20084481-0	2010	Wild Type p53 gene sensitizes rat C6 glioma cells to HSV-TK/ACV treatment in vitro and in vivo.	Acyclovir	60-63	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	10-13
20084481-6	2010	Exogenous wt-p53 significantly enhanced the sensitivity of TK positive C6 cells to ACV in vitro.	Acyclovir	83-86	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	13-16
20736469-9	2010	For individual antivirals, a major birth defect was diagnosed in 32 of 1561 infants (2.0%) with first-trimester exposure to acyclovir (adjusted POR, 0.82; 95% CI, 0.57-1.17) and in 7 of 229 infants (3.1%) with first-trimester exposure to valacyclovir (adjusted POR, 1.21; 95% CI, 0.56-2.62).	Acyclovir	124-133	cytochrome p450 oxidoreductase	Homo sapiens	144-147
20684612-4	2010	Therefore, we crystallized dCK in complex with ACV at the nucleoside phosphoryl acceptor site and UDP at the phosphoryl donor site.	Acyclovir	47-50	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	27-30
20684612-5	2010	The structure reveals that while ACV does bind at the dCK active site, it does so adopting a nonproductive conformation.	Acyclovir	33-36	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	54-57
20684612-7	2010	In comparison to ACV binding to HSV1-TK, in dCK, the nucleoside base adopts a different orientation related by about a 60 degrees rotation.	Acyclovir	17-20	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	44-47
20721704-1	2010	We report a case of herpes simplex virus (HSV) encephalitis (HSE) in an 11-year-old boy who recovered with acyclovir therapy but developed relapse after 2 weeks.	Acyclovir	107-116	hydroxysteroid 17-beta dehydrogenase 6	Homo sapiens	61-64
21154352-12	2010	Trifluridine (RR 1.12; 95% CI 1.04 to 1.21) and acyclovir (RR 1.11; 95% CI 1.05 to 1.19) appeared more effective than vidarabine.	Acyclovir	48-57	ribonucleotide reductase catalytic subunit M1	Homo sapiens	59-63
20810757-0	2010	A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs.	Acyclovir	117-132	deoxycytidine kinase	Homo sapiens	57-77
20810757-6	2010	CONCLUSION: The mutants of human dCK can be used as pyrimidine-specific PET reporter genes for imaging with (18)F-FEAU during treatment with acycloguanosine-based antiviral drugs.	Acyclovir	141-156	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	33-36
20736469-8	2010	RESULTS: Among 1804 pregnancies exposed to acyclovir, valacyclovir, or famciclovir in the first trimester, 40 infants (2.2%) were diagnosed with a major birth defect compared with 19,920 (2.4%) among the unexposed (adjusted POR, 0.89; 95% confidence interval [CI], 0.65-1.22).	Acyclovir	43-52	cytochrome p450 oxidoreductase	Homo sapiens	224-227
19853420-6	2010	In human volunteers, both F2 and F5 colloidal nanosuspensions prepared with EUD RS and RL respectively in drug to polymer ratio 1:3 sustained the oral absorption of ACV, expressed by the significant lower C(max), significant delayed T(max) and the significant higher HVD(t 50%C(max)).	Acyclovir	165-168	coagulation factor II, thrombin	Homo sapiens	26-35
20153888-7	2010	Effect of acyclovir on HIV-1 disease progression was defined by a primary composite endpoint of first occurrence of CD4 cell counts of fewer than 200 cells per microL, antiretroviral therapy initiation, or non-trauma related death.	Acyclovir	10-19	CD4 molecule	Homo sapiens	116-119
20153888-13	2010	In those with CD4 counts >or=350 cells per microL, aciclovir delayed risk of CD4 cell counts falling to <350 cells per microL by 19% (0.81, 0.71-0.93, p=0.002) INTERPRETATION: The role of suppression of herpes simplex virus type 2 in reduction of HIV-1 disease progression before initiation of antiretroviral therapy warrants consideration.	Acyclovir	54-63	CD4 molecule	Homo sapiens	14-17
20153888-13	2010	In those with CD4 counts >or=350 cells per microL, aciclovir delayed risk of CD4 cell counts falling to <350 cells per microL by 19% (0.81, 0.71-0.93, p=0.002) INTERPRETATION: The role of suppression of herpes simplex virus type 2 in reduction of HIV-1 disease progression before initiation of antiretroviral therapy warrants consideration.	Acyclovir	54-63	CD4 molecule	Homo sapiens	80-83
19853420-9	2010	The higher AUC(0-12) for both F2 and F5 reflected high relative bioavailability of 136.2% and 159.9% respectively compared to commercial ACV tablets.	Acyclovir	137-140	coagulation factor II, thrombin	Homo sapiens	30-39
21140560-1	2010	In vitro synergistic antiviral effect of interferon alpha-2b in combination with unithiol (an antioxidant) on diverse variants of Herpes simplex, including the clinical acyclovir-resistant isolates, was demonstrated.	Acyclovir	169-178	interferon alpha 2	Homo sapiens	41-60
19622750-7	2009	We show that chimeric gp43-UL54 enzymes that contain residues of helix N and helix P of UL54 are resensitized against foscarnet and acyclovir.	Acyclovir	132-141	DNA polymerase catalytic subunit	Human betaherpesvirus 5	27-31
19622750-7	2009	We show that chimeric gp43-UL54 enzymes that contain residues of helix N and helix P of UL54 are resensitized against foscarnet and acyclovir.	Acyclovir	132-141	DNA polymerase catalytic subunit	Human betaherpesvirus 5	88-92
19538011-2	2009	Two kinds of acyclovir (ACV)-entrapped mannosylated liposomes, i.e. ManN-ACV-lip and PAM-ACV-lip, were prepared by the use of mannosamine HCl (ManN) and p-aminophenyl-alpha-D-mannopyranoside (PAM), respectively.	Acyclovir	13-22	peptidylglycine alpha-amidating monooxygenase	Mus musculus	85-88
19538011-2	2009	Two kinds of acyclovir (ACV)-entrapped mannosylated liposomes, i.e. ManN-ACV-lip and PAM-ACV-lip, were prepared by the use of mannosamine HCl (ManN) and p-aminophenyl-alpha-D-mannopyranoside (PAM), respectively.	Acyclovir	13-22	peptidylglycine alpha-amidating monooxygenase	Mus musculus	192-195
19538011-2	2009	Two kinds of acyclovir (ACV)-entrapped mannosylated liposomes, i.e. ManN-ACV-lip and PAM-ACV-lip, were prepared by the use of mannosamine HCl (ManN) and p-aminophenyl-alpha-D-mannopyranoside (PAM), respectively.	Acyclovir	24-27	peptidylglycine alpha-amidating monooxygenase	Mus musculus	192-195
19538011-4	2009	The mean size of PAM-ACV-lip was significantly smaller than those of conventional ACV liposomes and ManN-ACV-lip due to the more conical packing parameter of mannose-conjugated phospholipid.	Acyclovir	21-24	peptidylglycine alpha-amidating monooxygenase	Mus musculus	17-20
19392906-1	2009	The main predictor of outcomes in herpes simplex virus (HSV) encephalitis (HSE) is the delay between hospital admission and initiation of acyclovir.	Acyclovir	138-147	hydroxysteroid 17-beta dehydrogenase 6	Homo sapiens	75-78
19392906-12	2009	Patients with HSE often present with severe underlying disease, chronic alcohol abuse, or atypical CSF findings, and such factors should not be allowed to delay diagnosis and administration of acyclovir.	Acyclovir	193-202	hydroxysteroid 17-beta dehydrogenase 6	Homo sapiens	14-17
19323627-3	2009	Corneal efflux by MRP5 was studied with bis(POM)-PMEA and acyclovir using rabbit and human corneal epithelial cells along with MRP5 over expressing cells (MDCKII-MRP5).	Acyclovir	58-67	ATP binding cassette subfamily C member 5	Homo sapiens	18-22
19323627-12	2009	However, MRP2 is involved in acyclovir efflux while MDR1 do not participate in this process.	Acyclovir	29-38	ATP binding cassette subfamily C member 2	Homo sapiens	9-13
19323627-9	2009	MRP5 inhibitors also diminished PMEA and acyclovir efflux.	Acyclovir	41-50	ATP binding cassette subfamily C member 5	Homo sapiens	0-4
18336632-3	2008	The present study investigates the effects of ethanol on the human peptide transporter 1 (hPepT1) which mediates the transport of di-and tripeptides as well as several orally administered peptidomimetic drugs such as beta-lactam antibiotics (e.g., penicillin), angiotensin-converting enzyme inhibitors, the anti-neoplastic agent bestatin, and prodrugs of acyclovir.	Acyclovir	355-364	cadherin 17	Homo sapiens	61-88
19323627-16	2009	In vivo ocular pharmacokinetics also revealed a significant increase in maximum aqueous humor concentration (C(max)) and area under the aqueous humor time curve (AUC) of acyclovir in the presence of MK-571, a specific MRP inhibitor.	Acyclovir	170-179	ATP binding cassette subfamily C member 1	Homo sapiens	218-221
19368128-6	2009	Apoptosis induction was established in this investigation as the mechanism of the ADV-RSV-TK gene therapy effect of acyclovir administration by caspase activity and subsequent CK 18 cleavage.	Acyclovir	116-125	keratin 18	Homo sapiens	176-181
19368128-9	2009	Significant anti-PARP 1 activity was found to be an ADV-RSV-TK treatment effect after acyclovir addition.	Acyclovir	86-95	poly(ADP-ribose) polymerase 1	Homo sapiens	17-21
18665439-0	2008	Acyclovir inhibits rat liver tryptophan-2,3-dioxygenase and induces a concomitant rise in brain serotonin and 5-hydroxyindole acetic acid levels.	Acyclovir	0-9	tryptophan 2,3-dioxygenase	Rattus norvegicus	29-55
18665439-5	2008	The aim of this study is to determine the effect of acyclovir, an antiviral used in the treatment of herpes simplex encephalitis, on rat liver tryptophan-2,3-dioxygenase activity in vitro and in vivo as well as on rat forebrain serotonin, 5-hydroxyindole acetic acid and norepinephrine levels.	Acyclovir	52-61	tryptophan 2,3-dioxygenase	Rattus norvegicus	143-169
18665439-6	2008	The results show that acyclovir inhibits tryptophan-2,3-dioxygenase activity in vitro and in vivo, with a concomitant rise in serotonin and 5-hydroxyindole acetic acid levels.	Acyclovir	22-31	tryptophan 2,3-dioxygenase	Rattus norvegicus	41-67
18336632-3	2008	The present study investigates the effects of ethanol on the human peptide transporter 1 (hPepT1) which mediates the transport of di-and tripeptides as well as several orally administered peptidomimetic drugs such as beta-lactam antibiotics (e.g., penicillin), angiotensin-converting enzyme inhibitors, the anti-neoplastic agent bestatin, and prodrugs of acyclovir.	Acyclovir	355-364	solute carrier family 15 member 1	Homo sapiens	90-96
18413388-0	2008	A new acycloguanosine-specific supermutant of herpes simplex virus type 1 thymidine kinase suitable for PET imaging and suicide gene therapy for potential use in patients treated with pyrimidine-based cytotoxic drugs.	Acyclovir	6-21	thyroid stimulating hormone receptor	Mus musculus	104-107
18413388-4	2008	With the use of an acycloguanosine-specific mutant of the enzyme, PET of HSV1-tk reporter gene expression can be successfully performed with acycloguanosine-based radiotracers without interference from pyrimidine-based antiviral drugs.	Acyclovir	19-34	thyroid stimulating hormone receptor	Mus musculus	66-69
18413388-4	2008	With the use of an acycloguanosine-specific mutant of the enzyme, PET of HSV1-tk reporter gene expression can be successfully performed with acycloguanosine-based radiotracers without interference from pyrimidine-based antiviral drugs.	Acyclovir	141-156	thyroid stimulating hormone receptor	Mus musculus	66-69